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A B S T R A C T
Background
Dyspnoea is a common symptom in chronic obstructive pulmonary disease (COPD). People who are hypoxaemic may be given long-
term oxygen relief therapy (LTOT) to improve their life expectancy and quality of life. However, the symptomatic benefit of home
oxygen therapy in mildly or non-hypoxaemic people with COPD with dyspnoea who do not meet international funding criteria for
LTOT (PaO2< 55 mmHg or other special cases) is unknown.
Objectives
To determine the efficacy of oxygen versus medical air for relief of subjective dyspnoea in mildly or non-hypoxaemic people with COPD
who would not otherwise qualify for home oxygen therapy. The main outcome was patient-reported dyspnoea and secondary outcome
was exercise tolerance.
Search methods
We searched the Cochrane Airways Group Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and
EMBASE, to November 2009, to identify randomised controlled trials. We handsearched reference lists of included articles.
Selection criteria
We only included randomised controlled trials of oxygen versus medical air in mildly or non-hypoxaemic people with COPD. Two
review authors independently assessed articles for inclusion.
Data collection and analysis
One review author completed data extraction and methodological quality assessment. A second review author then over-read evidence
tables to assess for accuracy.
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Main results
Twenty-eight trials on 702 patients met the criteria for inclusion; 18 trials (431 participants) were included in the meta-analysis. Oxygen
reduced dyspnoea with a standardised mean difference (SMD) of -0.37 (95% confidence interval (CI) -0.50 to -0.24, P < 0.00001).
We observed significant heterogeneity.
Authors’ conclusions
Oxygen can relieve dyspnoea in mildly and non-hypoxaemic people with COPD who would not otherwise qualify for home oxygen
therapy. Given the significant heterogeneity among the included studies, clinicians should continue to evaluate patients on an individual
basis until supporting data from ongoing, large randomised controlled trials are available.
P L A I N L A N G U A G E S U M M A R Y
Oxygen therapy for non-hypoxaemic chronic obstructive pulmonary disease
People with chronic obstructive pulmonary disease and breathlessness are sometimes prescribed oxygen therapy in an effort to reduce
the sensation of breathlessness. However, the use of oxygen to relieve breathlessness in people who do not have reduced levels of
oxygen in their blood stream (so called non-hypoxaemic people) remains controversial as not enough is known about its effectiveness.
Additionally, oxygen is not without risk, particularly in those who continue to smoke because of the risk of fire, and it is costly over the
long term. This review found that oxygen given to relieve symptoms can modestly reduce breathlessness with data collected from 28
trials (of which 18 had data which we could combine in meta-analyses). Given the magnitude of the effects and the variability in the
results of the individual studies, further study is warranted before drawing firm conclusions. This type of oxygen therapy is sometimes
called ’palliative oxygen’, because it is used to make patients feel better rather than to aim to increase life expectancy.
B A C K G R O U N D
Dyspnoea is a common symptom in chronic obstructive pul-
monary disease (COPD) that both patients and physicians find
frustrating. Dyspnoea is difficult to define because it is a combina-
tion of underlying pathology, a sensation involving neural path-
ways and a subjective perception on the part of the patient (ATS
1999). Descriptions of dyspnoea vary widely and depend, at least
in part, on a patient’s underlying disease, ethnic/racial background,
previous experiences and emotional state. Additionally, patients
often report dyspnoea that seems out of proportion to known un-
derlying lung disease. Typically, the recommendation is to relieve
dyspnoea by treating the underlying source but this is often not
successful or simply not possible. Patients are then left to try any
one of a number of interventions for which there is little evidence.
One such intervention is home oxygen therapy.
Home oxygen is commonly prescribed for individuals who are
hypoxaemic (PaO2 < 55 mmHg) or who are mildly hypoxaemic
(PaO2 55 to 59 mmHg) but who suffer from pulmonary hyper-
tension, cor pulmonale, secondary polycythaemia (haematocrit >
55%) or a combination. The evidence for home oxygen use is
provided by two studies, one by the Medical Research Council
Working Party (MRCWP 1981) and the other by the Nocturnal
Oxygen Therapy Trial Group (NOTT) (NOTTG 1980). These
studies evaluated the impact of long-term oxygen therapy (LTOT)
on survival in patients with COPD. They do not report on other
patient-valued outcome measures of oxygen therapy, i.e. symp-
tomatic treatment of dyspnoea, improved function or quality of
life outcomes. Current guidelines do not recommend symptomatic
therapy in dyspneic individuals who do not meet criteria for home
oxygen therapy. The goal of oxygen therapy for individuals who
are either mildly hypoxaemic or not hypoxaemic is not increased
life expectancy, but rather symptomatic or functional benefits (or
both). Symptomatic oxygen is sometimes called ’palliative oxygen’
for this reason. We will use the term palliative oxygen throughout
the review.
There are no systematic reviews on palliative oxygen in dyspneic
COPD patients who do not meet criteria for home oxygen ther-
apy. There are several Cochrane Reviews evaluating the use of
long-term oxygen therapy in patients with COPD but these do
not address the issue of palliative oxygen (Bradley 2005; Cranston
2005; Ram 2002). Bradley 2005 evaluated the efficacy of ambula-
tory oxygen using single assessment studies but the review differs
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from ours in several important ways. First, it includes all patients
with COPD and does not limit inclusion to non-hypoxaemic pa-
tients. Second, the primary aim of the review was to evaluate the
impact of oxygen on exercise capacity. While breathlessness was a
secondary outcome, the discussion was descriptive and no meta-
analysis was performed. The authors concluded that ambulatory
oxygen improved exercise capacity in patients with COPD but
noted that the efficacy of oxygen in patients who do not meet cri-
teria for long-term oxygen therapy and who do not have evidence
of hypoxaemia remains unknown (Bradley 2005). Ram 2002 eval-
uated the efficacy of long-term domiciliary oxygen therapy. In-
cluded studies were randomised controlled trials of ambulatory
oxygen at home; short-term assessment studies were excluded. All
studies included patients who were hypoxaemic (PaO2 < 7.3 kPa,
55 mmHg) at rest or on exertion. Ram 2002 concluded that fur-
ther study was required to assess the effectiveness of ambulatory
domiciliary oxygen therapy. A similar review evaluated the effect
of long-term oxygen therapy on survival and quality of life in pa-
tients with COPD and hypoxaemia (Cranston 2005); the review
also addressed breathlessness. Cranston 2005 concluded that long-
term oxygen therapy improved survival in people with COPD and
severe hypoxaemia but not in those with only mild to moderate
hypoxaemia.
All three reviews (Bradley 2005; Cranston 2005; Ram 2002) eval-
uated populations with the need for long-term oxygen therapy
and therefore do not answer the question of interest here, namely
is palliative oxygen a useful treatment for symptom relief?
Despite the lack of convincing evidence for benefit, palliative oxy-
gen for relief of breathlessness is commonly prescribed. A tele-
phone survey of Canadian physicians found that breathlessness was
a common reason for prescription of palliative oxygen (Stringer
2004). An email survey conducted by Abernethy et al reported
similar results, noting that a majority of palliative medicine clin-
icians and respiratory physicians in Australia and New Zealand
believe that palliative oxygen is beneficial; many cited refractory
dyspnoea as the reason for prescription (Abernethy 2005).
The discrepancy between current clinical practice and available
evidence has important implications. First, patients may be pre-
scribed ineffective treatments. Second, oxygen therapy is not a
benign intervention. Functional restriction from tubing, tanks or
concentrators, and the “sick role” may limit quality of life. Nasal
cannulae can irritate the nose and increase the risk of epistaxis.
Oxygen therapy carries a fire risk, particularly for smokers, but also
from other sources of ignition such as pilot lights (Robb 2003).
Hypercarbia may be exacerbated, though this risk is small. Third,
home oxygen therapy is expensive. If patients do not meet long-
term oxygen therapy criteria, then they must either pay for oxygen
therapy themselves or receive the intervention on compassionate
use grounds. Funding for home oxygen therapy is a common rea-
son for referral to hospice care in westernised countries. In Canada,
about 40% of patients receiving long-term oxygen therapy do not
meet current funding guidelines and receive oxygen therapy on a
compassionate use basis (Guyatt 2000).
This systematic review aimed to answer the following question:
’In mildly hypoxaemic or non-hypoxaemic COPD patients with
breathlessness, does oxygen therapy improve symptoms or func-
tion (or both)?’
O B J E C T I V E S
To determine the efficacy of oxygen for relief of dyspnoea in non-
hypoxaemic and mildly hypoxaemic individuals with chronic ob-
structive pulmonary disease. The major endpoints were: (1) im-
pact on dyspnoea; (2) impact on function or exercise tolerance (or
both); and (3) impact on quality of life.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all randomised controlled trials comparing oxygen
delivered via cylinder, concentrator or Douglas bag to medical air
or room air. Studies must have included the outcome of dyspnoea.
Studies did not have to be blinded. We only included studies eval-
uating long-term oxygen therapy or ambulatory domiciliary oxy-
gen therapy if assessments of the effects of oxygen on dyspnoea,
function or both following short-term administration were per-
formed and data were available.
Types of participants
We only included trials with adult patients with chronic obstruc-
tive pulmonary disease who were not hypoxaemic (room air PaO2
≥ 60 mmHg) or who were mildly hypoxaemic (room air PaO2
55 to 59 mmHg). Included patients must not have been on home
oxygen therapy at the time of enrolment.
Types of interventions
We included trials with oxygen versus medical air. Oxygen/air
had to be delivered by a non-invasive ventilatory method (nasal
cannula, Ventimask or mouthpiece). Allowable sources of oxygen
included cylinder, concentrator or Douglas bag. Inspired oxygen
concentrations between 25% and 100% were permitted. Oxygen/
air should have been delivered in single-dose fashion during ex-
ertion, in a short-burst fashion pre-or post-exertion, or on an as-
needed (PRN pro re nata meaning “take as needed”) basis over a
defined period of time.
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Types of outcome measures
Primary outcomes
Dyspnoea as measured by visual analogue scale (VAS), modified
Borg or dyspnoea numerical rating scale (NRS), or any other val-
idated scale for measuring dyspnoea. For those studies measuring
dyspnoea during exercise, isotime scores were used when available.
Isotime is defined as the end of exercise while receiving medical
air.
Secondary outcomes
1. Quality of life
2. Patient preference
3. Functional status as recorded on a recognised scale
Search methods for identification of studies
Electronic searches
We identified trials using the Cochrane Airways Group Specialised
Register of trials, which is derived from systematic searches of
bibliographic databases including the Cochrane Central Regis-
ter of Controlled Trials (CENTRAL), MEDLINE, EMBASE,
CINAHL, AMED and PsycINFO, and handsearching of respira-
tory journals and meeting abstracts (please see the Airways Group
search methods for further details). We searched all records in the
Specialised Register coded as ’COPD’ using the following terms:
(dyspnea OR dyspnoea OR breathless* or non-hypoxaemic or
non-hypoxemic) AND (oxygen* OR “inhalation therapy” OR 02
or LTOT or palliative)
The most recent search of the Cochrane Airways Group Specialised
Register was conducted in November 2009. We ran additional
searches of MEDLINE and EMBASE (1966 to 2009) using the
above search terms, adapted for each database as appropriate.
Searching other resources
We identified additional manuscripts by checking the reference
lists of those articles identified by searching the electronic databases
as well as by checking other reviews published on this topic.
Data collection and analysis
Selection of studies
Two review authors (HEU, APA) independently reviewed all rel-
evant articles identified by the search strategy. We selected trials
satisfying the following inclusion criteria:
1. randomised controlled trial;
2. adult patients with chronic obstructive pulmonary disease
and a normal oxygen saturation on room air;
3. oxygen as primary intervention;
4. oxygen supplied by non-invasive method (nasal canula,
Ventimask or mouthpiece);
5. available data on dyspnoea scores.
Data extraction and management
We assessed agreement regarding inclusion/exclusion of studies
using simple kappa statistics and resolved disagreements by con-
sensus and/or third investigator (DCC). For each included article,
one review author (HEU) extracted basic study parameters into
evidence tables summarising study design, patients, interventions,
outcomes and quality. A second review author (APA) then over-
read evidence tables to ensure accuracy. When necessary, we con-
tacted the authors of the primary studies to obtain additional in-
formation.
Assessment of risk of bias in included studies
We assessed included articles for internal and external validity. We
applied internal validity criteria to assess protection from bias in
the following domains: randomisation (sequence generation and
allocation concealment), blinding (of participants and assessors),
withdrawals/dropouts and full publication of outcomes. We as-
sessed external validity by evaluating patient description, interven-
tion description and reported dyspnoea outcomes.
Unit of analysis issues
Cross-over trials should be included in meta-analyses using re-
sults from paired analyses. However, these data are often not avail-
able. In these cases, we estimated standard errors using methods
described by Follman 1992. We estimated correlations between
repeat outcomes from P values when available. When correla-
tions could not be calculated, we used the lowest estimate from
other studies. In parallel-group studies that included blinded, ran-
domised, cross-over comparisons of oxygen to medical air dur-
ing exercise, we used outcomes from these evaluations to obtain
within-patient differences, and analysed these with data from other
cross-over studies.
Data synthesis
We combined all trial data using Review Manager software
(RevMan 2011). We performed meta-analysis for the primary and
secondary outcomes as appropriate and possible given available
data. Results from within-patient effects from both periods of
cross-over trials were to be used. In the case of studies evaluat-
ing multiple different doses of oxygen, we considered only the
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lowest dose in the analysis. We analysed breathlessness and exer-
cise tolerance as continuous outcomes. We calculated standardised
mean differences for breathlessness and exercise tolerance when
outcomes were measured on different scales. We performed all
analyses using a random-effects model. In the event that signifi-
cant statistical heterogeneity was observed, we applied a random-
effects model.
We inspected funnel plots to test for the presence of publication
bias.
Subgroup analysis and investigation of heterogeneity
We conducted the following a priori subgroup analyses:
1. studies by primary focus (sensation versus function versus
both);
2. studies including patients with exertional desaturation
versus studies including patients that did not desaturate on
exertion;
3. studies involving patients with baseline PaO2 less than 70
mmHg versus studies involving patients with baseline PaO2
greater than or equal to 70 mmHg; and
4. studies involving short-burst oxygen therapy versus those
not involving short-burst oxygen therapy.
Sensitivity analysis
We conducted the following sensitivity analyses:
1. analysis excluding trials that measure breathlessness only at
the end of maximal exercise testing (because of a difficulty in
comparing this assessment to studies measuring breathlessness at
the end of a six-minute walk test and/or at isotime of maximal
exercise testing);
2. analysis excluding trials where bias protection is poor;
3. analysis excluding trials where imputed quantities were
used; and
4. analysis excluding trials noted to be outliers (we undertook
this analysis to ensure that results were not influenced by the
presence or absence of these results).
R E S U L T S
Description of studies
The electronic searches yielded a total of 333 references, which
were screened on the basis of title/abstract or examination of
the full text. Of 28 studies included in this systematic review,
three assessed additional treatment arms which we included as
unique studies. Therefore this review summarises evidence from
31 study comparisons. Twenty-two were blinded, randomised,
cross-over trials (Davidson 1988; Dean 1992; Eaton 2002; Eves
2006; Garrod 1999; Ishimine 1995; Killen 2000; Knebel 2000;
Kurihara 1989; Laude 2006; Leach 1992; Lewis 2003; Maltais
2001; McDonald 1995; McKeon 1988a; McKeon 1988a; Moore
2009; Nandi 2003; O’Donnell 1997; Somfay 2001; Swinburn
1984; Woodcock 1981), five were randomised, controlled, par-
allel trials (Eaton 2006, Emtner 2003 (group 1)/Emtner 2003
(group 2); Haidl 2004, Rooyackers 1997 (group 1)/Rooyackers
1997 (group 2); Wadell 2001) and one was part of a non-ran-
domised parallel trial (Jolly 2001 (group 1)/Jolly 2001 (group 2)).
Three trials included two different comparisons (Emtner 2003
(group 1); Emtner 2003 (group 2); Jolly 2001 (group 1); Jolly
2001 (group 2); Rooyackers 1997 (group 1); Rooyackers 1997
(group 2). Four of the six parallel trials were designed to assess the
impact of oxygen versus air during pulmonary rehabilitation and
included blinded, randomised, cross-over evaluations of oxygen
versus medical air as part of the follow-up evaluation after com-
pletion of rehabilitation (Emtner 2003 (group 1)/Emtner 2003
(group 2); Jolly 2001 (group 1)/Jolly 2001 (group 2); Rooyackers
1997 (group 1)/Rooyackers 1997 (group 2); Wadell 2001).
In cross-over trials, participants receive two or more consecutive
treatments in random order (Sibbald 1998). Treatment A can be
compared to treatment B while each patient acts as his/her con-
trol, therefore decreasing concern over issues involving unknown
or unmeasured factors and requiring fewer subjects to answer
the same question, since between-participant variation is usually
greater than within-patient variation
Of the 31 included study comparisons, four had a main focus on
the sensation of breathlessness (Eaton 2002; Killen 2000; Moore
2009; Swinburn 1984), 17 were focused on function (Davidson
1988; Dean 1992; Emtner 2003 (group 1); Emtner 2003 (group
2); Eves 2006; Garrod 1999; Haidl 2004; Kurihara 1989; Laude
2006; Leach 1992; McDonald 1995; McKeon 1988b; Maltais
2001; O’Donnell 1997; Rooyackers 1997 (group 1); Rooyackers
1997 (group 2); Somfay 2001), and 10 were equally focused on
both sensation and function without reference to which was the
most important (Eaton 2006; Jolly 2001 (group 1); Jolly 2001
(group 2); Ishimine 1995; Knebel 2000; Lewis 2003; McKeon
1988a; Nandi 2003; Wadell 2001; Woodcock 1981). Twenty-four
of the included studies were single-assessment trials in controlled
laboratory conditions while four had a domiciliary component. It
should be noted that even in those trials with a domiciliary com-
ponent, the benefits of oxygen were evaluated using assessment
of function as the key outcome such as performance on a six-
minute walk test (6MWT). Dyspnoea was measured as follows:
modified Borg - 16 studies (Dean 1992; Eaton 2002; Emtner
2003 (group 1); Eves 2006; Garrod 1999; Haidl 2004; Jolly 2001
(group 1); Laude 2006; Lewis 2003; Maltais 2001; McDonald
1995; Moore 2009; O’Donnell 1997; Rooyackers 1997 (group
1); Somfay 2001; Wadell 2001), VAS - nine studies (Davidson
1988; Evans 1986; Killen 2000; Leach 1992; McKeon 1988a;
McKeon 1988b; Nandi 2003; Swinburn 1984; Woodcock 1981),
and other - three studies (Eaton 2006; Ishimine 1995; Kurihara
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1989). Three studies evaluated quality of life (Eaton 2002; Eaton
2006; McDonald 1995); this assessment did take place over a
longer period of time (i.e. weeks). Sample sizes of included studies
were small with a median of 20 participants per study and a mean
of 25 (standard deviation (SD) 18).
Patient characteristics
The 31 included study comparisons represented 702 participants,
all of them adults. Fifteen of the 28 studies had inclusion criteria
requiring moderate to severe COPD for study entry. Baseline PaO2
was provided in 20 of 28 studies; mean PaO2 was 70.8 mmHg (SD
5.9) (19 studies) and median PaO2 was 70.6 mmHg (one study).
Baseline oxygen saturation by pulse oximetry was provided by the
remaining eight studies as follows: mean 94.6% (SD 3.2) (Moore
2009), mean 94.4% (SD 1.6) (Lewis 2003), mean 95.7% (SD
0.8) (Somfay 2001), mean 91.9% (SD 5.2) (Nandi 2003), mean
93.9% (SD 2.3) (Laude 2006), mean 97.1% (SD 1.7) (Knebel
2000), median 94% (Killen 2000) and mean 93.2% (SD 0.8)
(Swinburn 1984). Mean baseline dyspnoea at rest was provided by
nine studies as follows: 1.8 (SD 1.1) by modified Borg and 24.2
(SD 19) by 100 mm VAS (Laude 2006), 0.4 (SD 0.5) by modified
Borg (Lewis 2003), 0.7 (1.0) by modified Borg (Eaton 2002), 0.56
(standard error (SE) 0.34) by modified Borg (Jolly 2001 (group
1) - non-desaturators) and 1.27 (SE 0.43) (Jolly 2001 (group 2) -
desaturators), 5.1 (SE 0.3) by dyspnoea index (O’Donnell 1997),
6.11 (SD 7.72) by 100 mm VAS (Evans 1986), 0.5 (SD 0.9) by 10
cm VAS (Knebel 2000), 4 (SD 0.94) by Medical Research Council
(MRC) dyspnoea grade (Woodcock 1981), and 17.1 (SD 0.91)
by chronic respiratory questionnaire (CRQ) (Eaton 2006).
Intervention characteristics
All included studies compared oxygen to medical air; two stud-
ies also included evaluation for the effects of a novel agent con-
taining both helium and oxygen (Eves 2006; Laude 2006). Both
oxygen and medical air were delivered via the same mechanism;
the most frequent mode of administration was nasal cannula
(16 studies) (Davidson 1988; Eaton 2002; Eaton 2006; Emtner
2003 (group 1); Garrod 1999; Haidl 2004; Jolly 2001 (group
1); Knebel 2000; Kurihara 1989; Lewis 2003; McDonald 1995;
McKeon 1988a; McKeon 1988b; Rooyackers 1997 (group 1);
Wadell 2001; Woodcock 1981) followed by mouthpiece/valve
(eight studies) (Dean 1992; Eves 2006; Laude 2006; Maltais 2001;
Moore 2009; O’Donnell 1997; Somfay 2001; Swinburn 1984)
and then mask (three studies) (Killen 2000; Leach 1992; Nandi
2003). Twenty-three of the included studies provided continu-
ous oxygen during activity, either 6MWT, endurance walk, shut-
tle walk, step test or cycle exercise (Davidson 1988; Dean 1992;
Eaton 2002; Eaton 2006; Emtner 2003 (group 1); Eves 2006;
Garrod 1999; Haidl 2004; Ishimine 1995; Jolly 2001 (group 1);
Jolly 2001 (group 2); Knebel 2000; Kurihara 1989; Laude 2006;
Leach 1992; Maltais 2001; McDonald 1995; McKeon 1988b;
O’Donnell 1997; Rooyackers 1997 (group 1); Rooyackers 1997
(group 2); Somfay 2001; Swinburn 1984; Wadell 2001; Woodcock
1981). The remaining four studies provided oxygen for a short,
pre-determined period immediately before exercise (Killen 2000;
Lewis 2003; McKeon 1988a; Nandi 2003), so-called ’short-burst
oxygen’. While several of the studies examining short-burst oxy-
gen also looked at oxygen delivered after exercise, these evalua-
tions were not included in this review as the outcome measure was
not one that could be combined with other studies for analysis.
One study provided oxygen at rest (Moore 2009). Doses of oxygen
ranged from 2 litres/min (L/min) to 5 L/min (median 3 L/min)
in 20 studies (Davidson 1988; Eaton 2002; Eaton 2006; Emtner
2003 (group 1); Emtner 2003 (group 2); Garrod 1999; Haidl
2004; Ishimine 1995; Jolly 2001 (group 1); Jolly 2001 (group
2); Killen 2000; Knebel 2000; Kurihara 1989; Leach 1992; Lewis
2003; McDonald 1995; McKeon 1988a; McKeon 1988b; Nandi
2003; Rooyackers 1997 (group 1); Rooyackers 1997 (group 2);
Wadell 2001; Woodcock 1981) and from 28% to 75% oxygen
(median 42%) in the remaining eight studies (Dean 1992; Eves
2006; Laude 2006; Maltais 2001; Moore 2009; O’Donnell 1997;
Somfay 2001; Swinburn 1984).
Risk of bias in included studies
Two independent review authors (HEU and APA) judged the qual-
ity of reporting (Jadad 1996), reported for each study in Table 1.
Disagreements were resolved by consensus. Methods were poorly
reported in most of the included studies.
Allocation
While all studies were described as randomised, we could verify
that sequence generation was adequate in only six studies. The
concealment of allocation was adequate in seven studies and in-
adequate in two (Figure 1). For the remaining trials we did not
have sufficient information to determine the risk of bias for their
allocation procedures.
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Blinding
Masking of treatment was undertaken in a number of studies. In
five studies we were unable to determine how blinding study par-
ticipants or investigators had been achieved. In 10 studies blinding
was not undertaken, or investigators knew which containers con-
tained oxygen (Garrod 1999; Haidl 2004; Killen 2000; Kurihara
1989; Lewis 2003; Rooyackers 1997 (group 1); Rooyackers 1997
(group 2); Somfay 2001; Swinburn 1984; Wadell 2001). For the
remaining 16 studies blinding of both study participants and study
investigators was attempted (Figure 1).
Incomplete outcome data
In 19 studies there were no withdrawals (Emtner 2003 (group 1);
Emtner 2003 (group 2); Eves 2006; Haidl 2004; Jolly 2001 (group
1); Jolly 2001 (group 2); Killen 2000; Leach 1992; Maltais 2001;
McDonald 1995; McKeon 1988a; McKeon 1988b; Nandi 2003;
O’Donnell 1997; Rooyackers 1997 (group 1); Rooyackers 1997
(group 2); Somfay 2001; Swinburn 1984; Woodcock 1981). Since
cross-over studies only analyse within-participant differences, par-
ticipants withdrawing from the first arm of treatment will not
have contributed to the analysis (Knebel 2000; Lewis 2003; Moore
2009). In the remaining studies we could not reliably ascertain
how missing data were handled (Figure 1).
Effects of interventions
Results from the meta-analysis are reported by outcome. All com-
parisons concern oxygen versus medical air.
Data from seven cross-over studies (Garrod 1999; Ishimine 1995;
Leach 1992; Maltais 2001; McKeon 1988b; Swinburn 1984;
Wadell 2001) could not be included in meta-analyses due to pre-
sentation of the outcomes data in a manner that could not be
summarised in meta-analyses and source data which could not be
obtained. Data from one cross-over study (Moore 2009) could
not be included in meta-analysis due to the fact that a statistically
significant order effect was noted in primary analysis of the data.
Additionally, it was noted that this study was an outlier. Data from
the two parallel-group studies (Eaton 2006; Haidl 2004) that did
not include any cross-over comparison of oxygen versus air were
also excluded from meta-analyses due to the methodologic issues
of combining data from cross-over and parallel studies in the same
analysis. Review of results from these studies that were not in-
cluded in the meta-analysis reveals that five (Haidl 2004; Ishimine
1995; Leach 1992; Maltais 2001; McKeon 1988b) demonstrated
improvement in dyspnoea with oxygen versus compressed air while
four (Eaton 2006; Garrod 1999; Swinburn 1984; Wadell 2001)
found no significant difference.
Primary outcome: dyspnoea
Data from 18 studies, representing 431 patients, were included in
this analysis (Davidson 1988; Dean 1992; Eaton 2002; Emtner
2003 (group 1); Emtner 2003 (group 2); Eves 2006; Jolly 2001
(group 1); Jolly 2001 (group 2); Killen 2000; Knebel 2000;
Kurihara 1989; Laude 2006; Lewis 2003; McDonald 1995;
McKeon 1988a; Nandi 2003; O’Donnell 1997; Rooyackers 1997
(group 1); Rooyackers 1997 (group 2); Somfay 2001; Woodcock
1981). Oxygen improved dyspnoea in mildly or non-hypoxaemic
patients with chronic obstructive pulmonary disease (COPD)
(standardised mean difference (SMD) -0.37, 95% confidence in-
terval (CI) -0.50 to -0.24, P < 0.00001, Analysis 1.1). We observed
no significant heterogeneity (I2 = 14%).
A priori subgroup analyses
Studies by primary focus
We divided studies by whether they focused on the sensation of
breathlessness, the patient’s physical function or both. Two review
authors (HEU and APA) made the group assignments indepen-
dently. Data were available for two studies focused on the sen-
sation of breathlessness (Eaton 2002; Killen 2000); oxygen im-
proved dyspnoea (SMD -0.39, 95% CI -0.66 to -0.12; P = 0.004,
Analysis 1.2). We observed no heterogeneity (I2 = 0%).
Data were available for 10 studies primarily focused on physical
function (Davidson 1988; Dean 1992; Emtner 2003 (group 1);
Emtner 2003 (group 2); Eves 2006; Kurihara 1989; Laude 2006;
McDonald 1995; O’Donnell 1997; Rooyackers 1997 (group 1);
Rooyackers 1997 (group 2); Somfay 2001); oxygen improved dys-
pnoea when compared to medical air (SMD -0.45, 95% CI -0.61
to -0.30; P < 0.00001). We observed no significant heterogeneity
(I2 = 0%). Data were available for six studies that focused on both
the sensation of breathlessness as well as physical function (Knebel
2000; Jolly 2001 (group 1); Jolly 2001 (group 2); Lewis 2003;
McKeon 1988a; Nandi 2003; Woodcock 1981); oxygen improved
dyspnoea (SMD -0.32, 95% CI -0.67 to 0.03; P = 0.07). We ob-
served significant heterogeneity (I2 = 54%).
We performed post-hoc sensitivity analyses for the subgroup fo-
cused on function as well as the subgroup focused on both sen-
sation and function after removing the outliers identified in the
main analysis. Results were stable following these analyses as fol-
lows:
1. Subgroup focused on both sensation and function (SMD -
0.15, 95% CI -0.43 to 0.14; P = 0.31, Analysis 1.11).
2. Subgroup focused on function (SMD -0.42, 95% CI -0.58
to -0.25; P < 0.00001, Analysis 1.11).
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Studies where exertional desaturation was noted
We divided studies by whether exertional desaturation was noted
during the study. Data were available for 15 studies where ex-
ertional desaturation was noted (Davidson 1988; Dean 1992;
Eaton 2002; Eves 2006; Jolly 2001 (group 2); Killen 2000; Knebel
2000; Kurihara 1989; Laude 2006; Lewis 2003; McDonald 1995;
McKeon 1988a; Nandi 2003; O’Donnell 1997; Rooyackers 1997
(group 1); Rooyackers 1997 (group 2)); oxygen improved dysp-
noea (SMD -0.33, 95% CI -0.46 to -0.20; P < 0.00001). We ob-
served no significant heterogeneity (I2 = 8%). Data were available
for four studies not noting exertional desaturation (Emtner 2003
(group 1); Emtner 2003 (group 2); Jolly 2001 (group 1), Somfay
2001; Woodcock 1981); oxygen improved dyspnoea when com-
pared to medical air (SMD -0.69, 95% CI -1.04 to -0.34; P <
0.0001, Analysis 1.4). We observed no significant heterogeneity
(I2 = 0%).
We performed post-hoc sensitivity analyses after removing the
outliers identified in the main analysis:
1. Subgroup noting exertional desaturation(SMD -0.31, 95%
CI -0.43 to -0.18; P < 0.00001).
2. Subgroup not noting exertional desaturation (SMD -0.57,
95% CI -0.95 to -0.19; P = 0.003).
Studies by mean PaO2
We divided studies into subgroups based on whether participants’
mean PaO2 was greater than or less than 70 mmHg (equivalent to
an oxygen saturation of 92.5% based on evaluation of the haemo-
globin-oxygen saturation curve). Data were available for 12 studies
whose participants had a mean PaO2 greater than or equal to 70
mmHg (Dean 1992; Eaton 2002; Emtner 2003 (group 1); Emtner
2003 (group 2); Jolly 2001 (group 1); Jolly 2001 (group 2); Killen
2000; Knebel 2000; Lewis 2003; McDonald 1995; O’Donnell
1997; Rooyackers 1997 (group 1); Rooyackers 1997 (group 2);
Somfay 2001; Woodcock 1981); oxygen improved dyspnoea when
compared to medical air (SMD -0.42, 95% CI -0.60 to -0.24; P <
0.00001, Analysis 1.5). We observed no significant heterogeneity
(I2 = 27%). Data were available for six studies whose participants
had a mean PaO2 of less than 70 mmHg (Davidson 1988; Eves
2006; Kurihara 1989; Laude 2006; McKeon 1988a; Nandi 2003);
oxygen improved dyspnoea when compared to medical air (SMD
-0.25, 95% CI -0.50 to 0.00; P = 0.05). We observed no signifi-
cant heterogeneity (I2 = 28%).
Studies by short-burst oxygen or not
We divided studies into subgroups based on whether or not they
provided short-burst oxygen. Data were available for four stud-
ies that provided short-burst oxygen (Killen 2000; Lewis 2003;
McKeon 1988a; Nandi 2003); short-burst oxygen did not improve
dyspnoea when compared to medical air (SMD 0.01, 95% CI -
0.26 to 0.28; P = 0.95, Analysis 1.3). We observed no significant
heterogeneity (I2 = 0%). Data were available for 14 studies that
provided continuous oxygen (Davidson 1988; Dean 1992; Eaton
2002; Emnter; Eves 2006; Jolly 2001 (group 1); Jolly 2001 (group
2); Knebel 2000; Kurihara 1989; Laude 2006; McDonald 1995;
O’Donnell 1997; Rooyackers 1997 (group 1); Rooyackers 1997
(group 2); Somfay 2001; Woodcock 1981); oxygen improved dys-
pnoea when compared to medical air (SMD -0.46, 95% CI -0.59
to -0.33; P < 0.00001). We observed no significant heterogeneity
(I2 = 0%).
A priori sensitivity analyses
Analysis excluding those trials measuring breathlessness at
end of exercise
Only three of the 19 studies included in this meta-analysis re-
ported dyspnoea measurements at the end of exercise (Emtner
2003 (group 1); Emtner 2003 (group 2); Eves 2006; Laude 2006).
The remaining studies measured breathlessness at isotime (defined
as the end of exercise while receiving medical air) or at the end of
a 6MWT. We repeated the analysis of the primary outcome with-
out these three studies. Results were stable following this analysis;
oxygen improved dyspnoea when compared to medical air (SMD
-0.37, 95% CI -0.54 to -0.21; P < 0.00001, Analysis 1.9). We
observed no significant heterogeneity (I2 = 30%).
Analysis excluding those trials where bias protection was
poor
Only seven of 26 included studies provided enough information to
conclude that allocation concealment was adequate (Eaton 2006;
Emtner 2003 (group 1); Emtner 2003 (group 2); Eves 2006;
Killen 2000; Knebel 2000; Laude 2006). Three of these studies
were excluded from meta-analysis due to data presentation, leaving
only four studies included in this sensitivity analysis (Emtner
2003 (group 1); Emtner 2003 (group 2); Eves 2006; Killen 2000;
Knebel 2000; Analysis 1.6). Oxygen did improve breathlessness
when compared to medical air, though the effect size was smaller
and the upper limit of the 95% CI crossed the null (SMD -0.25,
95% CI -0.55 to 0.06; P = 0.11). We observed no significant
heterogeneity (I2 = 0%).
Analysis excluding trials where imputed quantities were used
Only six of the 26 studies included in this systematic review pro-
vided sufficient data to allow calculation of SMD and variance
without the use of imputation (Dean 1992; Eaton 2002; Lewis
2003; Nandi 2003; O’Donnell 1997; Woodcock 1981; Analysis
1.7). We repeated the analysis of the primary outcome using only
data from these six studies. Results were stable following this anal-
ysis; oxygen improved dyspnoea when compared to medical air
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(SMD -0.36, 95% CI -0.64 to -0.09; P < 0.00001). We observed
significant heterogeneity (I2 = 59%).
Post-hoc analyses
Review of both the forest plot and a funnel plot of the main analysis
revealed the presence of four outlying results. We performed a
sensitivity analysis after removing these outliers (Dean 1992; Jolly
2001 (group 1); Jolly 2001 (group 2); Somfay 2001). The benefit
of oxygen was preserved (SMD -0.33, 95% CI -0.45 to -0.22, P
< 0.00001).
Review of the study design (including inclusion/exclusion criteria),
patient characteristics (including baseline measures of pulmonary
function as well as baseline oxygen saturation and/or PaO2), and
intervention characteristics of the four studies identified as outliers
did not reveal any specific differences from the remaining studies
as a whole, nor any differences that could explain the discordant
results. As noted above, one additional study (Moore 2009) was
not included in meta-analysis due to an order effect. We also noted
this study to be an outlier.
After observing that short-burst oxygen did not improve dyspnoea
when compared to medical air, we repeated the analysis of the
primary outcome without studies providing short-burst oxygen
due to the concern that inclusion of these studies could result in
underestimation of the benefits of oxygen over medical air. The
SMD did change slightly with this analysis(SMD -0.46, 95% CI -
0.59 to -0.33; P < 0.00001, Analysis 1.3) versus SMD -0.37, 95%
CI -0.50 to -0.24; P < 0.00001).
Secondary outcome: quality of life (QOL)
Three studies in 145 people examined changes in QOL (Eaton
2002; Eaton 2006; McDonald 1995). This outcome could not be
combined in meta-analysis due to both data presentation and het-
erogeneity with respect to measurement of the outcome. There-
fore, this outcome is presented in a descriptive fashion.
Two studies examined QOL by both disease-specific (chronic res-
piratory questionnaire (CRQ)) and generic measures (short form
36 (SF-36)) (Eaton 2006 and Eaton 2002). Additionally, par-
ticipants filled out the Hospital Anxiety and Depression Scale
(HADS). The first study (Eaton 2006) was a randomised, con-
trolled, parallel-group trial that included three arms as follows:
oxygen, medical air or usual care. The only domain of the CRQ to
show statistical significance (P = 0.045) was emotional function;
the greatest improvement was in the usual care group who received
neither oxygen nor air. The second study (Eaton 2002) demon-
strated statistically significant improvements in all domains of the
CRQ (fatigue, P = 0.02; emotional function, P = 0.006; mastery,
P = 0.008; total, P = 0.002) and both domains of the HADS (anx-
iety, P = 0.009; depression, P = 0.05) for oxygen when compared
to medical air. Significant improvements in several domains of the
SF-36 were also noted. These included role physical (P = 0.01),
general health, (P = 0.04), social functioning (P = 0.05) and role
emotional (P = 0.02). A third study measured only disease-specific
QOL using the CRQ (McDonald 1995). Statistically significant
improvements were noted in all domains for the comparison of
baseline scores to those after six weeks of oxygen therapy (P < 0.02
for all domains). However, when scores after oxygen therapy were
compared to scores after air, no statistically or clinically significant
differences were seen.
Secondary outcome: patient preference
Three included studies in 85 patients examined patient preference
at a time when participants were still blinded (Eaton 2002; Killen
2000; McDonald 1995). This outcome could not be combined in
meta-analysis; a description of results from each trial follows.
The first study (Eaton 2002) simply asked patients if they were
interested in the clinical provision of oxygen at study completion.
Interestingly, 14 patients (41%) identified as having either an acute
or a short-term response to oxygen did not wish to be considered
for continued therapy. Eleven of these 14 (76%) cited poor tol-
erability or acceptability as the reason. The second study (Killen
2000) was a study of short-burst oxygen immediately before and
after walking up a flight of steps. Again, patients were asked which
gas they preferred. Of 18 patients, five preferred oxygen before as-
cending the stairs, three preferred air and three had no preference.
The remaining seven patients preferred to receive oxygen at the
top of the stairs. As a group, there was no significant preference for
oxygen therapy (P = 0.119 by binomial theory). The third study
(McDonald 1995) included both acute assessments and a domi-
ciliary portion that lasted six weeks with each gas. At the end of the
study, patients were asked which six-week period they preferred.
Fifty percent preferred the period on oxygen; the remaining 50%
either preferred air or had no preference.
D I S C U S S I O N
Oxygen was effective at reducing dyspnoea in mildly and non-
hypoxaemic people with chronic obstructive pulmonary disease
(COPD) who would not otherwise qualify for home oxygen ther-
apy, with a standardised mean difference (SMD) of -0.37 (95%
CI -0.50 to -0.24, P < 0.00001) translating into a reduction of
0.78 cm on a 10 cm visual analogue scale (VAS) and a reduction of
0.9 points on a 0 to 10 numerical rating scale (NRS). This result
could also be considered clinically significant as Ries et al (Ries
2005) concluded that a minimally clinically important difference
is a change of one point on the Borg scale and a change of 10 to
20 mm on a VAS and a recent consensus statement confirms this
recommendation and expands it to cover other aetiologies (Booth
2006). Additionally, emerging data from a population of heart
failure patients with chronic breathlessness has suggested that be-
tween 0.5 and 1 improvement in a 0 to 10 NRS is symptomatically
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meaningful to patients, equating to a one-point change on the
global impression of change in breathlessness scale (unpublished
data calculation from Oxberry S, Thesis: Opioids in heart failure,
University of York 2010).
Interestingly, a subgroup analysis evaluating the effectiveness of
oxygen at reducing dyspnoea when the gas was delivered as a short
burst prior to exercise failed to show a similar benefit (SMD 0.01,
95% CI -0.26 to 0.28; P = 0.06). The reason for this difference
is not clear but there is a possibility that it may be related to a
physiologic effect of oxygen that is present during longer-term
administration of the gas and that is not generated when oxygen is
administered for only a short period. One might argue that there
could be an effect resulting from wearing nasal cannulae during
continuous gas delivery, but this should have been addressed by
the presence of a control arm using medical air. Regardless of the
explanation for this finding, it has important implications as it
suggests that those individuals demonstrating clinical benefit from
oxygen therapy should receive the gas continuously in order to
achieve maximum benefit.
Quality of life (QOL) was also evaluated by three of the stud-
ies included in this review (Eaton 2002; Eaton 2006; McDonald
1995). Data were conflicting with two (Eaton 2006; McDonald
1995) of three studies demonstrating no improvements in QOL
with oxygen versus medical air and a third study demonstrating
statistically significant improvements in all domains of the chronic
respiratory questionnaire (CRQ), both domains of the Hospital
Anxiety and Depression Scale (HADS), and several domains of
the short form 36 (SF-36) with oxygen versus medical air. The
reason for the conflicting results is not clear. The two studies by
Eaton et al included different patient populations, with one study
(Eaton 2006) recruiting participants at the time of hospital dis-
charge after an exacerbation and the other (Eaton 2002) enrolling
patients with stable disease on an “optimal” medical regimen who
had completed a pulmonary rehabilitation programme. Addition-
ally, the positive study (Eaton 2002) was a cross-over trial while
the negative study (Eaton 2006) was a parallel trial. Both stud-
ies followed patients while they received either oxygen or medi-
cal air at home for a six-week period. Based on inclusion criteria
alone, the study that failed to show a QOL benefit may have in-
cluded a more heterogeneous population, making it more difficult
to demonstrate a difference between populations. The third study
(McDonald 1995) also enrolled stable patients but the study was
small (n = 24) so the sample size may not have been large enough
to detect a change in QOL. Finally, it is possible that the benefits
of oxygen with regard to QOL were overshadowed by the incon-
veniences and functional restrictions associated with home oxygen
therapy. Further research is needed.
The final outcome assessed was patient preference. This is a par-
ticularly important outcome given the subjective nature of dysp-
noea and general difficulty in quantifying this distressing symp-
tom. Several important issues were highlighted through this re-
view. There were clearly a subset of patients who preferred oxygen,
though there was not a statistically significant difference between
the preference for oxygen and the preference for medical air. It was
not clear whether individuals who reported a decrease in dyspnoea
with oxygen were the same individuals who identified oxygen as
the preferred gas. One study (Eaton 2002) did report on the pref-
erences of those individuals identified as oxygen “responders”, with
41% of these individuals not wishing to be considered for further
therapy; the main reason cited was the inconvenience or poor tol-
erability and is consistent with findings from one other large study
of oxygen therapy (Currow 2007). Hence, patient QOL factors
such as convenience and adverse consequences should be taken
into consideration when trying to decide whether to prescribe oxy-
gen as a treatment for dyspneic palliative care patients who may be
already burdened by their illness and other life changes prominent
in the advanced-illness setting.
Our systematic review and meta-analysis does have several limita-
tions, in addition to those resulting from limitations in the current
body of literature addressing the effect of oxygen on dyspnoea in
non-hypoxaemic individuals with COPD. While all of the studies
included in this review excluded individuals already qualifying for
home oxygen therapy according to current guidelines, the popu-
lation still included a wide range of baseline oxygen saturation/
PaO2. This variability could affect the results if there is a rela-
tionship between oxygen saturation and response of dyspnoea to
oxygen administration. We addressed this issue by performing a
subgroup analysis that divided studies by baseline PaO2 (either
greater than or equal to 70 mmHg or less than 70 mmHg). Addi-
tionally, few studies provided information regarding baseline dys-
pnoea and/or baseline functional status (as assessed by six-minute
walk test (6MWT) or other standard assessment). As a result, the
population likely included patients with varied perceptions of dys-
pnoea as well as varied functional capacities. Palliative oxygen is
most commonly prescribed for seriously ill patients nearing end
of life; however, these patients are less likely to be participants in
many of the studies reviewed here, especially those with an exer-
cise or exertional component. The applicability of the findings in
this review to all COPD patients requiring palliative oxygen is un-
clear. Finally, we observed significant heterogeneity in most of our
analyses. This is likely due to the fact that the studies included in
this review, while all comparing oxygen to medical air and evaluat-
ing impact on exercise and dyspnoea, were performed with differ-
ent methodologies. The variability in baseline oxygen saturation/
PaO2, dyspnoea and functional status may also have contributed
to the observed heterogeneity. Importantly, this heterogeneity did
not influence the overall results of the meta-analysis as evidenced
by the fact that results of all analyses were stable after removal of
four outlying studies.
Finally, in considering these results, one needs to be sure not to
forget the downsides of administering oxygen. Oxygen is costly
and, with current stresses on healthcare systems in many coun-
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tries, this needs to be taken into account. The effect of oxygen
administration on quality of life also remains unclear. We now
have additional therapies, including tiotropium and pulmonary
rehabilitation, for dyspnoea that were not available at the time that
most of the studies included in this review were ongoing. Future
trials should consider a strategy whereby oxygen is evaluated as an
add-on to these other measures.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Oxygen can relieve dyspnoea in mildly and non-hypoxaemic peo-
ple with chronic obstructive pulmonary disease (COPD) who
would not otherwise qualify for home oxygen therapy. Impact on
quality of life cannot be determined from currently available data.
The small sample sizes and heterogeneity amongst studies included
in this review make it difficult to provide general recommen-
dations. Until we have evidence from adequately powered ran-
domised controlled trials addressing this question, decisions re-
garding the prescription of palliative oxygen to people with COPD
and refractory dyspnoea not meeting criteria for long-term oxy-
gen therapy should continue to be made on an individual basis. A
larger trial is forthcoming (Currow 2007).
Implications for research
A large trial addressing this issue is needed in order to inform
the decision to use palliative oxygen better in this patient popu-
lation. Consideration should also be given to outcome measures
such as health-related quality of life and health care utilisation.
Additionally, studies aimed at better defining which specific sub-
groups of patients with COPD may derive an incremental im-
provement in their dyspnoea in response to supplemental oxygen
are required. Finally, these interesting data from the COPD setting
should prompt evaluations in a broader range of illnesses compli-
cated by debilitating breathlessness.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Davidson 1988
Methods Randomised, double-blind, cross-over (though not explicitly stated in methods)
Participants Inclusion criteria: exercise tolerance limited by breathlessness secondary to severe chronic
airflow obstruction
Exclusion criteria: angina, impaired cardiac function or locomotor disability that might
contribute to exercise limitation
17 patients
Gender not specified
Mean age 64.4 (SEM 2.1)
Mean FEV1 (L) 0.79 (SEM 0.03)
Mean FVC (L) 2.14 (SEM 0.11)
Mean PaO2 (mmHg) 64.51 (SEM 2.25)
Interventions Compressed air (4 L/min) versus oxygen (2, 4 or 6 L/min) during 6MWT, cycle ergometer
test or endurance walk
Outcomes 6MWT: dyspnoea at 1-minute intervals and distance covered as well as recovery time
Cycle ergometer test: minute ventilation, heart rate, CO2 production, oxygen consump-
tion, HbSaO2%, and dyspnoea at 1-minute intervals
Endurance walk: endurance time and distance covered as well as recovery time (assessed
by asking patients when they were no longer feeling breathless)
Dyspnoea measured by 10 cm VAS marked at each end with “not at all breathless” and
“extremely breathless”
Notes Authors only reported outcomes for oxygen at 4 L/min
QS (walking) = 2
QS (cycle) = 1
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, other informa-
tion not available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
Breathlessness
Unclear risk Described as double-blind, other informa-
tion not available
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Information not available
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Dean 1992
Methods Randomised, double-blind, cross-over
Participants Inclusion criteria: age > 50, DLCO < 80% predicted, extensive smoking history, resting
PaO2 > 55 mmHg
Exclusion criteria: active coronary artery disease, congestive heart failure, vascular, or-
thopedic or neurologic problems that would interfere with cycling; “reduced DLCO” to
exclude those with asthma
12 patients
All male
Age > 50 but specifics not reported
Mean FEV1 (L) 0.89 (SEM 0.09)
Mean FVC (L) 2.37 (0.20)
Mean DLCO mL/min/mmHg 9.8 (SEM 1.5)
Mean PaO2 (mmHg) 71 (SEM 2.6)







Dyspnoea measured by modified Borg numbered 1 to 10 for which the 2 extremes were
“none” and “extremely severe”
Notes Dyspnoea was the primary limiting symptom in each patient
QS = 4
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, other information
not available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
Breathlessness
Unclear risk Described as double-blind, other information
not available
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Information not available
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Eaton 2002
Methods Randomised, double-blind, controlled
Participants Inclusion criteria: COPD as defined by ATS criteria, exertional dyspnoea impacting
daily activities, not fulfilling criteria for LTOT, exertional desaturation (O2 saturation
<= 88%), ex-smoker, clinically stable for 2 months with standard optimal medical care,
completion of a formal 6-week pulmonary rehabilitation programme




Mean age 57.1 (SD 9.3)
Mean FEV1 (% predicted) 25.9 (SD 8)
Mean oxygen saturation 94.5 (SD 1.9)
Mean PaO2 (mmHg) 69 (SD 7.5)
Mean PaCO2 (mmHg) 43.5 (SD 5.25)
Interventions Compressed air (4 L/min) versus oxygen (4 L/min) during both 6MWT and 6-week
period at home during which patients were instructed “to use flow rate of 4 L/min
intranasally for any activity during which they would normally experience dyspnoea.”
Outcomes Physiologic measure: resting, 2-min, and 6-min SaO2, walk distance, pre- and post-walk
modified Borg dyspnoea scores; HRQOL measures: CRQ, HADS, SF-36 scores
Domiciliary programme: use of air or oxygen-filled cylinder
Dyspnoea measured by modified Borg
Notes QS = 4
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
Breathlessness
Low risk “Patients were randomly assigned in a double-
blinded manner to cylinder air or O2 (light
weight aluminium: standard 2,000-2,200 psi
fill: 145 L, weight 2.04 kg (4.5 lbs) fitted with a
conserving demand gas delivery system (Oxy-
matic; Chad Therapeutics, Inc., Chatsworth,
CA, USA). All cylinders were painted pink,
prefilled with either air or O2 and identifiable
only by a unique cylinder number, ensuring
blinding of both participants and observers.”
19Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Eaton 2002 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk “A mixed model approach to crossover trials
was employed, which used information from
all patients, including those who did not com-
plete both time periods. Treatment and or-
der of treatment (to exclude a carryover effect)
were included in the model with the patient as
a random effect.”
Eaton 2006
Methods Randomised, double-blind, controlled, parallel-group trial
Participants Inclusion criteria: 78 hospital inpatients with an acute exacerbation of COPD; moderate
or severe COPD as defined by the British Thoracic Society criteria; exertional dyspnoea
interfering with daily activity; resting PaO2 > 60 mmHg at discharge; ability to complete
HRQOL questionnaires
Exclusion criteria: current smoker; severe comorbidity likely to cause death within the
6-month study period; resident of a long-term facility in which SBOT is available;
hypercapnia (PaCO2 > 45 mmHg)
Interventions Cylinder oxygen (2 L/min) versus cylinder air (2 L/min) versus usual care during 6-month
domiciliary period. Patients were given standardised instructions “to use they cylinder
gas at 2 L/min via nasal prongs, as necessary for distressing or limiting breathlessness”.
No short-term assessments were performed
Outcomes FEV1 and FVC
ABG
CRQ, SF-36 and HADS
Healthcare utilisation
Dyspnoea measured by CRQ




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomised using com-
puter-generated randomisation numbers.”
Allocation concealment (selection bias) Low risk “Allocation of cylinders was by a separate
member of the research team not involved
in patient assessment.”
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Eaton 2006 (Continued)
Blinding (performance bias and detection
bias)
Breathlessness
Low risk “To ensure double-blinding, cylinders, pre-
filled with air or oxygen, were identifi-
able only by a unique cylinder number.
Cylinders were painted pink to ensure they
would not be used in routine clinical care.
”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Information not available
Emtner 2003 (group 1)
Methods Randomised, double-blind, controlled
Participants Inclusion criteria: COPD that is clinically stable with no recent exacerbations, FEV1 <
50% predicted, ratio of FEV1 to VC < 65%, resting PaO2 > 55 mmHg, SpO2 >= 88%
during constant work rate test while breathing room air
Exclusion criteria: symptomatic cardiovascular comorbidity or other disease that might
contribute to exercise limitation, regular participation in a formal exercise programme
or participation in a formal rehabilitation programme within the past 2 years
15 patients
10 male and 5 female
Mean age 67 (SD 10)
Mean FEV1 (L) 1.13 (SD 0.30)
Mean FVC (L) 2.74 (SD 0.9)
Mean TLC (L) 7.3 (SD 1.4)
Mean RV (L) 4.2 (SD 1.2)
Mean DLCO mL/min/mmHg 13.1 (SD 5)
Mean PaO2 73.8 (SD 6.2)
Mean PaCO2 42.3 (SD 3.2)
Interventions Compressed air versus oxygen (30%) during constant work rate exercise




QOL data with CRDQ and SF-36
Dyspnoea measured by modified Borg
Notes QS = 5
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of generating randomisation schedule
not available
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Emtner 2003 (group 1) (Continued)
Allocation concealment (selection bias) Low risk Sealed envelopes used to conceal generated
randomisation sequence from study investiga-
tors
Blinding (performance bias and detection
bias)
Breathlessness
Low risk “The nasal cannula tubing was connected to
the appropriate tank (compressed air or oxy-
gen) by an unblinded investigator. Patient and
staff did not know which gas mixture the pa-
tient received (...) Exercise intensity was subse-
quently adjusted, considering the subject’s dys-
pnoea and fatigue sensations, by blinded ther-
apists.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No participants withdrew from this arm of
treatment
Emtner 2003 (group 2)
Methods Randomised, double-blind, controlled trial
Participants Inclusion criteria: COPD that is clinically stable with no recent exacerbations, FEV1 <
50% predicted, ratio of FEV1 to VC < 65%, resting PaO2 > 55 mmHg, SpO2 >= 88%
during constant work rate test while breathing room air
Exclusion criteria: symptomatic cardiovascular comorbidity or other disease that might
contribute to exercise limitation, regular participation in a formal exercise programme
or participation in a formal rehabilitation programme within the past 2 years
14 patients
8 male and 6 female
Mean age 65 (SD 11)
Mean FEV1 (L) 1.12 (0.37)
Mean FVC (L) 2.9 (0.8)
Mean PaO2 (mmHg) 74.9 (8.7)
Interventions Compressed air versus oxygen (30%) during constant work rate exercise




QOL data with CRDQ and SF-36
Dyspnoea measured by modified Borg
Notes QS = 5
Risk of bias
Bias Authors’ judgement Support for judgement
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Emtner 2003 (group 2) (Continued)
Random sequence generation (selection
bias)
Unclear risk Method of generating randomisation
schedule not available
Allocation concealment (selection bias) Low risk Sealed envelopes used to conceal generated
randomisation sequence from study inves-
tigators
Blinding (performance bias and detection
bias)
Breathlessness
Low risk “The nasal cannula tubing was connected
to the appropriate tank (compressed air or
oxygen) by an unblinded investigator. Pa-
tient and staff did not know which gas mix-
ture the patient received.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No participants withdrew from this arm of
treatment
Eves 2006
Methods Randomised, double-blind, cross-over
Participants Inclusion criteria: clinically stable moderate to severe COPD




Mean age 65 (SD 11)
Mean FEV1 (L) 1.66 (0.59)
Mean FVC (L) 3.81 (0.99)
Mean PaO2 (mmHg) 68.3 (6.4)
Interventions Medial air versus 40% oxygen versus heliox versus heliox/oxygen during constant-load
cycling
Outcomes Exercise time, lung volumes, respiratory mechanics, dyspnoea
Dyspnoea measured by modified Borg
Notes QS = 4
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “During the other two visits, four constant-
load symptom-limited exercise trials were per-
formed in a random order”
Allocation concealment (selection bias) Unclear risk Information on concealment of allocation not
available
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Eves 2006 (Continued)
Blinding (performance bias and detection
bias)
Breathlessness
Low risk “Throughout exercise, humidified gases were
passed into a reservoir bag and supplied
through a low-resistance two-way breathing
valve (2700 series, Hans Rudolph, Kansas City,
MO). The patients were blinded to the gas mix-
ture used and were asked not to talk during,
or for a short period after exercise due to the
change in vocal tone with helium.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study
Garrod 1999
Methods Randomised, single-blind, cross-over (though not explicitly stated in methods)
Participants Inclusion criteria: FEV1 < 1 L, less than 15% and 200 mL reversibility with beta agonists,
no exacerbations in the previous 4 weeks, desaturation of at least 4% on baseline walk
Exclusion criteria: not stated
15 patients
Mean age 66 (range 50 to 75)
Mean FEV1 (L) 0.83 (0.28)
Mean PaO2 (mmHg) 62.86 (9.3)
Interventions Oxygen (2 L/min) versus air (2 L/min) versus demand flow oxygen during shuttle walk
test
Outcomes Distance on shuttle walk test
Borg score before and immediately after each shuttle walk test
SaO2
Dyspnoea measured by modified Borg
Notes QS = 2
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, no other infor-
mation available
Allocation concealment (selection bias) Low risk “The codes for randomisation were held in
sealed envelopes.”
Blinding (performance bias and detection
bias)
Breathlessness
High risk Single-blind; participants breathed
through identical cylinders
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Garrod 1999 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk One participant failed to complete exercise
test
Haidl 2004
Methods Randomised, controlled, parallel-group trial
Participants Inclusion criteria: COPD diagnosis (per “current clinical guidelines”), FEV1/FVC <
70%, pCO2 > 45 mmHg at rest on 2 different days or increase in pCO2 after cycle
testing > 45 mmHg, pO2 at rest > 55 mmHg, mean nocturnal oxygen saturation was
>= 90%, peak TR jet < 30 mmHg by ECHO
Exclusion criteria: malignant disease, left heart failure or other significant comorbidities
(e.g. severe renal failure, severe diabetes)
28 patients (14 in each arm)
13 male and 1 female in each arm
Mean age - arm 1 65.7 (6.7)
Mean age - arm 2 64.5 (6.4)
Mean FEV1, % predicted - arm 1 38.8 (8.4)
Mean FEV1, % predicted - arm 2 42.7 (11.8)
Mean PaO2 (mmHg) - arm 1 65.6 (6.2)
Mean PaO2 (mmHg) - arm 2 67.3 (6.5)




Endurance time every 6 months for 3 years
Dyspnoea measured by modified Borg
Notes QS = 2
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Information not available
Allocation concealment (selection bias) Low risk Participants’ randomisation status was un-
known to staff performing their test
Blinding (performance bias and detection
bias)
Breathlessness
High risk Control group received only usual care
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Haidl 2004 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Both treatment groups complete at 1 year
when assessment was undertaken. Study
planned to measure differences at 3 years
but attrition rates prevented this
Ishimine 1995
Methods Randomised, cross-over study
Participants Inclusion criteria: male with “stable” COPD or chronic bronchitis, moderate to severe
obstruction, PaO2 > 60 torr at rest
Exclusion criteria: not available (not specified in Cochrane translation)
22 patients
All men
Mean age 69 (SD 7)
Mean FEV1 (L) 1.02 (0.51)
Mean FVC (L) 2.26 (0.57)
Mean PaO2 (mmHg) 75.9 (8.6)
Interventions Room air versus compressed air (3 L/min) versus oxygen (3 L/min) during 6MWT
Outcomes Dyspnoea during 6WMT as well as distance walked on 6MWT
Dyspnoea measured by a questionnaire involving 8 questions; each question was an-
swered on a 100 mm horizontal line with anchors from the modified Borg
Notes Translated from Japanese so had to work from translation sheet
QS = 2
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, other information not avail-
able
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
Breathlessness
Unclear risk Placebo controlled; blinding of assessors could not be
ascertained
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Information not available
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Jolly 2001 (group 1)
Methods Randomised
Double-blind
Cross-over (though not explicitly stated in methods)
Participants Inclusion criteria: COPD patients (ATS grade II/III) with at least 30 days of clinical
stability; participating in respiratory rehab programme, FEV1 < 55% and/or FEV1 ratio
< 50%, resting PaO2 > 60 mmHg
Exclusion criteria: peripheral vascular disease; cardiac failure; active CAD
9 patients
Mean age 70 (SEM 3)
All male
Mean FEV1 (L) 0.9 (SEM 0.8)
Mean FVC (% predicted) 63 (SEM 6)
Mean TLC (L) 7.43 (SEM 0.4)
Mean RV (L) 4.42 (SEM 0.39)
Mean oxygen saturation 95.8 (SEM 0.46)
Mean PaO2 (mmHg) 79 (SEM 3)
Mean PaCO2 (mmHg) 40 (SEM 1.6)
Interventions Room air versus compressed air (3, 6, 9, 12 L/min) versus oxygen (3, 6, 9, 12 L/min)
during 6MWT - amount of oxygen increased based upon any desaturation during exercise
Outcomes Distance walked
Oxygen saturation/heart rate during walk
Final dyspnoea score
Dyspnoea measured by modified Borg
Notes QS = 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; other informa-
tion not available
Allocation concealment (selection bias) High risk “One person, who knew the randomly as-
signed sequence, opened the valve and reg-
ulated the gas flow as requested by an-
other technician, who walked behind the
patient recording the SaO2 measured by
pulse oximetry (SpO2) values. Both this
technician and the patient were blind about
which gas was added.”
Blinding (performance bias and detection
bias)
Breathlessness
Low risk “Two indistinguishable cylinders located at
the middle of the corridor, one with com-
pressed air (CA) and one with oxygen, were
connected by a Y-piece to a 15-m tube end-
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Jolly 2001 (group 1) (Continued)
ing in a nasal cannula.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed
Jolly 2001 (group 2)
Methods Randomised, double-blind, cross-over (though not explicitly stated in methods)
Participants Inclusion criteria: COPD patients (ATS grade II/III) with at least 30 days of clinical
stability; participating in respiratory rehab programme, FEV1 < 55% and/or FEV1 ratio
< 50%, resting PaO2 > 60 mmHg
Exclusion criteria: peripheral vascular disease; cardiac failure; active CAD
11 patients
Mean age 67 (SEM 2)
10 male and 1 female
Mean FEV1 (L) 0.9 (SEM 0.8)
Mean FVC (% predicted) 68 (SEM 8)
Mean TLC (L) 7.07 (SEM 0.6)
Mean RV (L) 4.19 (SEM 0.45)
Mean oxygen saturation 94.7 (SEM 0.27)
Mean PaO2 (mmHg) 74 (SEM 2)
Mean PaCO2 (mmHg) 41 (SEM 1.2)
Interventions Room air versus compressed air (3, 6, 9, 12 L/min) versus oxygen (3, 6, 9, 12 L/min)
during 6MWT - amount of oxygen increased based upon any desaturation during exercise
Outcomes Distance walked
Oxygen saturation/heart rate during walk
Final dyspnoea score
Dyspnoea measured by modified Borg
Notes QS = 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; other informa-
tion not available
Allocation concealment (selection bias) High risk “One person, who knew the randomly as-
signed sequence, opened the valve and reg-
ulated the gas flow as requested by an-
other technician, who walked behind the
patient recording the SaO2 measured by
pulse oximetry (SpO2) values. Both this
technician and the patient were blind about
28Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Jolly 2001 (group 2) (Continued)
which gas was added.”
Blinding (performance bias and detection
bias)
Breathlessness
Low risk “Two indistinguishable cylinders located at
the middle of the corridor, one with com-
pressed air (CA) and one with oxygen, were
connected by a Y-piece to a 15-m tube end-
ing in a nasal cannula.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All participants completed
Killen 2000
Methods Randomised, single-blind, cross-over (though not explicitly stated in methods)
Participants Inclusion criteria: COPD predominantly related to smoking and who were being con-
sidered for symptomatic oxygen therapy; all had stairs at home and found that ascending
these produced dyspnoea; desaturation to below 90% on ascent of 22 steps
Exclusion criteria: history of ischaemic heart disease, left ventricular failure or other cause
of reduced mobility such as severe arthritis; already on long term oxygen or fulfilling
criteria for long-term oxygen therapy
18 patients
Mean age 67.5 (IQR 60.5 to 74.3)
8 male and 10 female
Median FEV1 (L) 0.53 (IQR 0.45 to 0.76)
Median DLCO (% predicted) 44 (IQR 28 to 64)
Median oxygen saturation on room air 94 (IQR 91 to 95)
Interventions Oxygen (2 L/min) versus compressed air 5 minutes before and/or 5 minutes after as-
cending 22 steps
Outcomes Time of ascent
Pulse rate, oxygen and dyspnoea at rest, immediately after the ascent, and at 1-minute
intervals thereafter
Dyspnoea measured by 100 mm VAS with “not at all breathless” at one end and “ex-
tremely breathless” at the other end
Notes QS = 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The order of the ascents was determined
by randomisation within a Latin square.”
Allocation concealment (selection bias) Unclear risk Information on concealment of allocation
not available
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Killen 2000 (Continued)
Blinding (performance bias and detection
bias)
Breathlessness
High risk “During the five minutes before and after
these ascents they breathed from a cylinder
of either compressed air or oxygen, deliv-
ered at 2 l/min via a face mask, in a single
blind manner.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed
Knebel 2000
Methods Randomised, double-blind, cross-over
Participants Inclusion criteria: adults with OLD due to AAT deficiency; FEV1 < 70% and FEV1/
FVC ratio < 0.70
Exclusion criteria: FEV1 < 1 L; hospitalisation in preceding 3 weeks; conditions pro-
hibiting or limited exercise; current use of oxygen; inability to understand English
31 patients
Mean age 47 (SD 7) (Range 33-69)
22 male and 13 female
Mean FEV1 (% predicted) 48 (SD 13) (range 27 to 69)
Mean TLC (% predicted) 105 (SD 14) (range 73 to 136)
Baseline oxygen saturation 97.1% (SD 1.7) (range 92 to 100)
Interventions Oxygen (4 L/min) versus compressed air (4 L/min) during 6MWT
Outcomes Distance walked during 6MWT
Oxygen sat during walk
Heart rate
Breathing frequency
Dyspnoea measured by 10 cm horizontal VAS with “No shortness of breath” on the left
and “Shortness of breath as bad as it can be” on the right
Notes QS = 5
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A table of random numbers identified the or-
der of administration.”
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
Breathlessness
Low risk “The tanks were covered so neither the patient
nor the researcher knew which gas was being
used.”
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Knebel 2000 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk “Two patients were unable to complete all of
the walks because of unrelated problems”. Data
on remaining participants analysed in the study
Kurihara 1989
Methods Randomised, single-blind, cross-over
Participants Inclusion criteria: “COPD”
Exclusion criteria: none mentioned (working from Cochrane translation)
14 patients
11 male and 3 female
Mean age 62 (10.2)
Mean FEV1 (L) 0.67 (0.23)
Mean FVC, % predicted 58.3 (6.2)
Mean PaO2 (mmHg) 68.8 (8.9)
Interventions Dyspnoea by modified Borg scale and distance walked on treadmill
Outcomes Dyspnoea by modified Borg scale and distance walked on treadmill
Dyspnoea measured by modified Borg scale numbered 1 to 10 for which the two extremes
were “none” and “extremely severe”




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; no other information
available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
Breathlessness
High risk Single-blind study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Information not available
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Laude 2006
Methods Randomised, controlled, cross-over study (though not explicitly stated in methods)
Participants Inclusion criteria: COPD confirmed by an FEV1 /FVC ratio < 80% predicted and limited
bronchodilator reversibility; exertion dyspnoea defined by Borg ? 3 after exercise; no
history of recent exacerbation
Exclusion criteria: not explicitly stated
82 patients
Gender not specified
Mean age 69.7 (range 46 to 84)
Mean FEV1 (L) 1.1 (0.4)
Mean FVC (L) 2.6 (0.8)
Baseline oxygen saturation 93.9% (2.3)
Interventions Heliox 28 (72%He/28%O2) versus heliox 21 (79%He/21%O2) versus oxygen 28
(72%N2/28%O2) versus medical air (79%N2/21%O2) during treadmill exercise
Outcomes Dyspnoea at rest and on exercise
SaO2
Heart rate
Dyspnoea measured by 100 mm VAS and modified Borg
Notes QS = 1
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; no other infor-
mation presented
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
Breathlessness
Unclear risk “In all tests, the investigator carried the
gas cylinder walking beside the patient and
gave no encouragement. Patients were in-
structed not to speak while breathing the
gas mixtures and for 2 min afterwards to
avoid unblinding.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Intention-to-treat population reported;
specific details of how missing data were
handled in the analysis not available
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Leach 1992
Methods Randomised, double-blind, cross-over (though not explicitly stated in methods)
Participants Inclusion criteria: severely reduced exercise tolerance secondary to chronic respiratory
disease; no previous experience of exercise testing




Mean FEV1 (L) 0.74 (0.25)
Mean FVC (L) 1.94 (0.51)
Mean PaO2 (mmHg) 65.5 (17.6)
Interventions Oxygen (2, 4 or 6 L/min) versus compressed air (4 L/min) during 6MWT and endurance
walk (walk as far as possible and stop when unable to go further)
Outcomes Distance walked in metres (both 6MWT and endurance walk)
Dyspnoea score by 10 cm VAS (both 6MWT and endurance walk at end exercise)
Dyspnoea measured by 10 cm VAS with “not at all breathless” at one end and “extremely
breathless” at the other
Notes QS = 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The order of the four tests in which the gas
was carried by the patient was randomised
on each day.”
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
Breathlessness
Unclear risk “The subject and the investigator were
blinded to the flow rate and type of gas sup-
plied, although in practice the investigator
was frequently able to determine those pa-
tients having oxygen from the oxygen sat-
uration shown by ear oximetry.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed
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Lewis 2003
Methods Randomised, single-blind, placebo-controlled, cross-over trial (though not explicitly
stated in methods)
Participants Inclusion criteria: moderate to severe COPD according to BTS criteria, significant self-
reported dyspnoea, on optimal treatment, no exacerbation of disease for >= 4 weeks prior
to study with exacerbation defined as “a deterioration in respiratory symptoms requiring
treatment with corticosteroids or antibiotics or both”
Exclusion criteria: significant limiting or unstable co morbidities
18 patients
16 male and 2 female
Mean age 68.7 (SD 10.1)
Mean FEV1 (L) 0.91 (SD 0.36)
Baseline oxygen saturation 94.4 (SD 1.6)
Interventions Oxygen (2 L/min) versus air (2 L/min) prior to 6MWT
Outcomes Baseline heart rate, saturation and dyspnoea
HR and saturation every minute during 6MWT
Dyspnoea at end of 6MWT
Distances in metres
HR, saturation and dyspnoea every 30 seconds during recovery until patient returned
to baseline
Notes QS = 2
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, other informa-
tion not available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
Breathlessness
High risk “...identical cylinders in a single-blind fash-
ion.”
Incomplete outcome data (attrition bias)
All outcomes
High risk 2 withdrawals: “All completed walks were
included for analysis.”
Maltais 2001
Methods Randomised, double-blind, cross-over (though not explicitly stated in methods)
Participants Inclusion criteria: “moderate to severe” COPD with diagnosis based on previous or
current smoking history and PFTs (including spirometry, lung volume and CO diffusing
capacity), “stable” disease
Exclusion criteria: clinical cardiovascular, neurological or any condition that could alter
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Maltais 2001 (Continued)
the capacity to perform an exercise test according to medical history, physical exam,
resting and exercise electrocardiogram and chest x-ray
14 patients
Gender not specified
Mean age 63 (SEM 3)
Mean FEV1 (L) 1.04 (SEM 0.07)
Mean FVC (L) 2.64 (SEM 0.15)
Mean PaO2 (mmHg) 85 (SEM 4)
Interventions Room air versus oxygen (75%) during exercise testing
Outcomes Single leg blood flow
Respiratory rate (RR), tidal volume (TV), minute ventilation (MV), oxygen uptake
Dyspnoea and leg fatigue perception
Arterial and venous PO2 and PCO2 and pH
Dyspnoea measured by modified Borg
Notes QS = 2
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients performed two exercise tests in a
random order”
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
Breathlessness
Low risk “Patients and the physician supervising the
exercise tests were blinded as to which in-
spiratory gas was used.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study
McDonald 1995
Methods Randomised, double-blind, cross-over
Participants Inclusion criteria: stable severe COPD, resting PaO2 > 60 mmHg, exertional dyspnoea
sufficient to interfere with daily activities, non-smoker, no exacerbations in preceding 3
months, use of maximal bronchodilator and/or corticosteroid therapy
Exclusion criteria: symptomatic cardiac dysfunction; angina pectoris; locomotor disabil-
ity
26 patients
24 male and 2 female
Mean age 73 (SD 6)
Mean FEV1 (L) 0.9 (SD 0.4)
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McDonald 1995 (Continued)
Mean DLCO (mL/min/mmHg) 10.6 (SD 2.4)
Mean oxygen saturation 94 (SD 2.1)
Mean PaO2 (mmHg) 69 (SD 8.5) and range 58 to 82
Mean PaCO2 (mmHg) 41 (SD 3.3)
Interventions Oxygen (4 L/min) versus compressed air (4 L/min) over long-term (successive 6-week
periods during which patients were instructed to use portable gas cylinder during “any
activity that would normally induce dyspnea”) as well as in acute setting (6MWT and
step test)
Outcomes Acute: 6-minute walk distance and step test at study beginning as well as beginning of
each 6-week period plus modified Borg dyspnoea score at the end of each exercise test
Chronic: QOL by CRDQ and symptom scores from patient diaries
Dyspnoea measured by modified Borg
Notes QS = 4
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, other information
not available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
Breathlessness
Low risk Cylinders had identical appearance
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study
McKeon 1988a
Methods Randomised, double-blind, cross-over (though not explicitly stated in methods)
Participants COPD with “significant disability with exertional dyspnoea despite treatment with in-
haled and oral bronchodilators”; “stable condition” at the time of the study
20 patients
13 male and 7 female
Mean age 63.2 (SD 10)
Mean FEV1 (L) 0.79 (SD 0.29)
Mean FVC (L) 2.30 (SD 0.7)
Mean TLC (% predicted) 122 (SD 24)
Mean RV (% predicted) 206 (SD 60)
Mean DLCO (% predicted) 55 (SD 32)
Mean oxygen saturation 90 (SD 3) (range 84 to 96)
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McKeon 1988a (Continued)
Mean PaO2 (mmHg) 58 (SD 9) (range 43 to 82)
Mean PaCO2 (mmHg) 44 (SD 9) (range 31 to 62)
Baseline PaO2 (mmHg) on room air 58 (SD 9) and range 43 to 82
Interventions Compressed air versus oxygen via nasal prongs at 2.5 L/min for 10 minutes prior to




Breathlessness before and each minute during exercise
Maximum distance walked
Dyspnoea measured by 300 mm VAS
Notes QS = 2
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, information not
available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
Breathlessness
Low risk “Neither the patient nor the operator knew
whether compressed air or supplemental
oxygen had been given. Patients were told
that both cylinders contained oxygen, but
in different concentrations.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study
McKeon 1988b
Methods Double-blind, randomised, controlled, cross-over trial
Participants COPD with “significant disability with exertional dyspnoea despite treatment with in-
haled and oral bronchodilators”; “stable condition” at the time of the study
21 patients
11 women and 10 men
Mean age 62 (SD 9)
Mean FEV1 (L) 0.77 (SD 0.40)
Mean FEV1 (% predicted) 29 (SD 13)
Mean FVC (L) 2.00 (SD 0.89)
Mean FVC (% predicted) 58 (SD 20)
Mean RV (L) 3.53 (SD 0.94)
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McKeon 1988b (Continued)
Mean TLC (L) 5.97 (SD 1.34)
Mean baseline PaO2 (mmHg) 66.4 (SD 11)
Mean baseline PaCO2 (mmHg) 43.9 (SD 8.8)
Interventions Oxygen (4 L/min) versus air (4 L/min) during treadmill test
Outcomes Heart rate, arterial oxygen saturation, breathlessness, maximum walking distance
Dyspnoea measured by 300 mm VAS
Notes QS = 5
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, no other infor-
mation available
Allocation concealment (selection bias) Low risk Cylinders prepared by technician not in-
volved in study
Blinding (performance bias and detection
bias)
Breathlessness
Low risk Identical cylinders used in the study
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study
Moore 2009
Methods Double-blind, randomised, controlled, cross-over (though not explicitly stated in meth-
ods)
Participants Inclusion criteria: patients with a clinical diagnosis of COPD attending the respiratory
laboratory for routine breathing tests
Exclusion criteria: use of short-term bronchodilators within 4 hours; receipt of supple-
mental oxygen within 20 minutes
52 (51 included in analysis)
40 male and 11 female
Mean age 72.6 (SD 9.7)
Mean FEV1 (L) 1.40 (SD 0.78)
Mean FEV1 (% predicted) 54.7 (SD 24.9)
Mean FVC (L) 2.82 (SD 1.03)
Mean FVC (% predicted) 86.3 (SD 21.0)
Mean FEV1/FVC (%) 44 (SD 14.5)
Baseline oxygen saturation (%) 94.6 (SD 3.2)
Interventions Oxygen (44%) versus medical air via mouthpiece
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Moore 2009 (Continued)
Outcomes Breathing frequency, cardiac frequency, oxygen saturation, dyspnoea
Dyspnoea measured by modified Borg
Notes QS = 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; information not
available
Allocation concealment (selection bias) Unclear risk Information not available




Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All participants completed the study
Nandi 2003
Methods Randomised, double-blind, controlled trial
Participants Inclusion criteria: FEV1 < 60% predicted with less than 15% reversibility to inhaled
salbutamol, a smoking history of more than 20 pack-years, exertional desaturation of at
least 4% on pulse oximetry during submaximal exertion (corridor walking)
Exclusion criteria: any other complicating medical condition
34 patients
18 male and 16 female
Mean age 68 (SD 5.98)
Mean FEV1 (L) 0.88 (SD 0.34)
Mean oxygen saturation 91.9 (5.2) with range 76 to 97
Mean PaO2 (mmHg) 57.83 (10.88)* with range 38.56 to 78.76
*22 patients
Baseline oxygen saturation on room air 91.9 (SD 5.2) with range 76 to 97
Interventions Oxygen (28% at 4 L/min) versus compressed air (4 L/min) before exercise
Outcomes Physiologic measure: resting, 2-min and 6-min SaO2, walk distance, pre- and post-walk
modified Borg dyspnoea scores; HRQOL measures: CRQ, HADS, SF-36 scores
Domiciliary programme: use of air or oxygen-filled cylinder
Dyspnoea measured by 100 mm VAS with end points of “not breathless at all” and “the
most breathless I have ever been”
Notes QS = 3
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Nandi 2003 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, information not
available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
Breathlessness
Low risk “...neither the patient nor the test supervi-
sor was aware of the gas mixture being used,
or of oxygen saturation levels which were
recorded by another observer.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study
O’Donnell 1997
Methods Double-blind, randomised, cross-over, placebo-controlled trial
Participants Inclusion criteria: advanced chronic airway limitation (FEV1 < 60% predicted), mild
hypoxaemia (did not meet criteria for home oxygen, referred to an exercise programme
because they were sedentary/had poor exercise tolerance/experienced severe activity-
related breathlessness with a modified dyspnoea index of 6 or less*
Exclusion criteria: clinical evidence of significant cardiovascular disease, other pulmonary
disease (including cor pulmonale), or other disorders that could contribute to dyspnoea
or exercise limitation
11 patients
7 male and 4 female
Mean age 68 (SEM 2)
Mean FEV1 (% predicted) 0.97 (SEM 0.13)
Mean FVC (% predicted) 2.27 (SEM 0.25)
Mean TLC (% predicted) 6.98 (SEM 0.5)
Mean RV (% predicted) 4.39 (SEM 0.33)
Mean DLCO (mL/min/mmHg) 8.8 (SEM 1.1)
Mean PaO2 (mmHg) 74 (SEM 3)
Mean PaCO2 (mmHg) 41 (SEM 2)
Interventions Room air versus 60% O2 (L/min not provided) on endurance cycle exercise test
Outcomes Subjective ratings of breathlessness (defined as “the sensation of labored or difficult
breathing”) and perceived leg effort (defined as “the level of difficulty experienced during
pedaling”) by modified Borg scale at rest, every minute during exercise, and at peak
exercise
Objective measures of cardiovascular function, ventilatory function, gas exchange (via
ABG)
Measurements were taken during steady-state rest and during constant-load exercise
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O’Donnell 1997 (Continued)
Dyspnoea measured by modified Borg with zero indicating “no breathlessness” and 10
representing “the most severe breathlessness that had ever been experienced or that they
could imagine experiencing”
Notes QS = 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; no other infor-
mation available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
Breathlessness
Low risk Identical breathing apparatus used in the
study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All participants completed
Rooyackers 1997 (group 1)
Methods Randomised, blinded study
Participants Inclusion criteria: hypoxaemia (SaO2 < 90%) at maximal exercise and an increase in
alveolar-arterial difference in oxygen tension of at least 2 kPa from rest to maximal
exercise during maximal incremental exercise, former smoker, no medication changes
during the study
Exclusion criteria: resting PaO2 < 64 mmHg, mean nocturnal SaO2 < 90%, mean
pulmonary artery pressure > 25 mmHg measured at rest by Doppler echocardiography,
and neuromuscular or cardiovascular
12 patients
10 male and 2 female
Mean age 59 (SD 13)
Mean FEV1 (L) 1.2 (SD 0.5)
Mean TLC (% predicted) 110 (SD 11)
Mean DLCO (% predicted) 40 (SD 15)
Mean PaO2 (mmHg) 76.5 (SD 9.0)
Mean PaCO2 (mmHg) 36.8 (4.5)
Interventions Room air (RA) versus oxygen (4 L/min) during maximal incremental cycle exercise test,
single-stage exercise test and 6MWT
Outcomes PFTs (spirometry and DLCO)
Maximal incremental exercise - ABG, minute ventilation, carbon dioxide production,
breathlessness every 3 minutes and at end of exercise
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Rooyackers 1997 (group 1) (Continued)
Single-stage cycle exercise test - endurance cycling time, minute ventilation, carbon
dioxide production, breathlessness every 3 minutes and at end of exercise
Activities of daily life - 6MWT distance with continuous SaO2 measurement and dys-
pnoea score at end; stair-climbing in 5 minutes; weightlifting during 3 minutes
Dyspnoea measured by modified Borg
Notes QS = 1
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer random number generator (see Nonoyama
2007)
Allocation concealment (selection bias) Unclear risk Central randomisation (see Nonoyama 2007)
Blinding (performance bias and detection
bias)
Breathlessness
High risk Room air compared with compressed oxygen
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study
Rooyackers 1997 (group 2)
Methods Randomised
Participants Inclusion criteria: hypoxaemia (SaO2 < 90%) at maximal exercise and an increase in
alveolar-arterial difference in oxygen tension of at least 2 kPa from rest to maximal
exercise during maximal incremental exercise, former smoker, no medication changes
during the study
Exclusion criteria: resting PaO2 < 64 mmHg, mean nocturnal SaO2 < 90%, mean
pulmonary artery pressure > 25 mmHg measured at rest by Doppler echocardiography,
and neuromuscular or cardiovascular
12 patients
10 male and 2 female
Mean age 63 (SD 5)
Mean FEV1 (L) 1.0 (SD 0.4)
Mean TLC (% predicted) 110 (SD 22)
Mean DLCO (% predicted) 30 (SD 15)
Mean PaO2 (mmHg) 71.3 (SD 15)
Mean PaCO2 (mmHg) 39.8 (8.3)
Interventions Room air (RA) versus oxygen (4 L/min) during maximal incremental cycle exercise test,
single-stage exercise test, and 6MWT
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Rooyackers 1997 (group 2) (Continued)
Outcomes PFTs (spirometry and DLCO)
Maximal incremental exercise - ABG, minute ventilation, carbon dioxide production,
breathlessness every 3 minutes and at end of exercise
Single-stage cycle exercise test - endurance cycling time, minute ventilation, carbon
dioxide production, breathlessness every 3 minutes and at end of exercise
Activities of daily life - 6MWT distance with continuous SaO2 measurement and dys-
pnoea score at end; stair-climbing in 5 minutes; weightlifting during 3 minutes
Dyspnoea measured by modified Borg
Notes QS = 1
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer random number generator (see Nonoyama 2007)
Allocation concealment (selection bias) Low risk Central randomisation (see Nonoyama 2007)
Blinding (performance bias and detection
bias)
Breathlessness
High risk Room air compared with compressed oxygen.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study
Somfay 2001
Methods Randomised, single-blind, controlled, cross-over trial (though not explicitly stated in
methods)
Participants Inclusion criteria: severe COPD (FEV1 < 40% predicted), no more than mildly hypox-
aemic (O2 sat at rest > 92% and during exercise > 88%) (None had previously qualified
for home oxygen.)
Exclusion criteria: clinically manifest cor pulmonale, severe cardiovascular comorbidity
or other disease that might contribute to dyspnoea or exercise limitation
10 patients
6 male and 4 female
Mean FEV1 (L) 0.92 (SD 0.43)
Mean FVC (% predicted) 76 (SD 15)
Mean TLC (L) 7.3 (SD 1.5)
Mean RV (L) 4.3 (SD 1.3)
Baseline oxygen saturation 95.7 % (SD 0.8)
Interventions Compressed air versus oxygen (30%, 50%, 75% or 100%) during constant work rate
test (with constant work rate determined by 75% of peak work rate in incremental test
at study beginning)
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Dyspnoea measured by modified Borg
Notes QS = 1
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; no other infor-
mation available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
Breathlessness
High risk Single-blind study
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study
Swinburn 1984
Methods Randomised, single-blind, cross-over trial
Participants Inclusion criteria: advanced obstructive airways disease but in “stable clinical state”
5 patients
Exclusion criteria: not explicitly stated
Interventions Room air (RA) versus oxygen (60%) during incremental cycle exercise test
Outcomes Breathlessness
Maximum ventilation reached on exercise
Duration of exercise
Notes QS = 1
Risk of bias
Bias Authors’ judgement Support for judgement
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Swinburn 1984 (Continued)
Random sequence generation (selection
bias)
Unclear risk Described as randomised; other informa-
tion not available
Allocation concealment (selection bias) Unclear risk Information not available




Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study
Wadell 2001
Methods Randomised, single-blind, controlled trial
Participants Inclusion criteria: under the age of 75 years, stopped smoking at least 6 months before
entering the study, hypoxaemia during exercise (<= 92% in 6MWT), FEV1 < 70% pre-
dicted, PaO2 > 60 mmHg at rest, no infection in the 3 weeks preceding study enrolment,
no change in medical treatment in the month preceding enrolment
Exclusion criteria: any past or present major illness, such as cardiac, orthopedic or neu-
rological disease that might have interfered with exercise performance
20 patients
10 in air group and 10 in oxygen group
Median age - air group 69 (60 to 72) and oxygen group 65 (52 to 73)
Median FEV1, % predicted - air group 51.6 (24 to 65.7) and oxygen group 39.3 (23.3
to 59.1)
Median PaO2 (mmHg) - air group 69.8 (59.3 to 85.5) and oxygen group 71.3 (64.5 to
87)
Interventions Oxygen (5 L/min) versus air (5 L/min) during 6MWT on treadmill - baseline effect of
2 interventions as complete study involved training over an 8-week period
Outcomes 6MWT distance
modified Borg dyspnoea score
HR
Borg perceived exertion score
Dyspnoea measured by modified Borg
Notes QS = 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Picking allocation from container (see
Nonoyama 2007)
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Wadell 2001 (Continued)
Allocation concealment (selection bias) Unclear risk Not enough information available to deter-
mine how order of treatment group assign-
ment was concealed from investigators
Blinding (performance bias and detection
bias)
Breathlessness
High risk Single-blind study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Information not available
Woodcock 1981
Methods Randomised, double-blind, cross-over
Participants Inclusion criteria: fixed airways obstruction, “moderate or severe breathlessness on exer-
tion” (method of defining not stated), normal or low PaO2
Exclusion criteria: none stated
10 patients
9 male and 1 female
Mean age 62 (range 43 to 70)
Mean FEV1 (L) 0.71 (SD 0.29)
Mean FVC (L) 2.65 (SD 1.041)
Mean PaO2 (mmHg) 72 (SD 11.3)
Mean PaCO2 (mmHg) 34.1 (SD 4.5)
Interventions Compressed air (4 L/min) versus oxygen (100% delivered at 4 L/min) during treadmill
test and 6MWT
Outcomes Dyspnoea at end exercise
6-minute walk distance
Treadmill test distance
Dyspnoea measured by 10 cm VAS
Notes QS = 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
Breathlessness
Low risk Compressed air versus oxygen delivered via
coded unmarked cylinders
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Woodcock 1981 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study
6MWT: six-minute walk test; AAT: Alpha 1 anti-trypsin; ABG: Arterial blood gas; ATS: American Thoracic Society; BTS: British
Thoracic Society; CAD: Coronary artery disease; CO: Carbon monoxide; COPD: chronic obstructive pulmonary disease; CRDQ
: Chronic respiratory disease questionnaire; CRQ: chronic respiratory questionnaire; DLCO: Diffusing capacity of the lung for
carbon monoxide; ECHO; Echocardiogram; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; HAD:
Hospital Anxiety and Depression Scale; hr: hour; HR: Heart rate; HRQOL: health-related quality of life; IQR: interquartile range;
LTOT: long-term oxygen relief therapy; LV: Left ventricle; OLD: Obstructive lung disease; PaO2: partial pressure of oxygen in
arterial blood; pCO2: Partial pressure of carbon dioxide; PFT: Pulmonary function test; pO2: Partial pressure of oxygen; QS: quality
score; RV: Right ventricle; RVSP:- RV systolic pressure; SBOT: short-burst oxygen therapy; SD: standard deviation; SEM: standard
error of the mean; SF-36: Short Form 36; SPO2: Oxygen saturation; TLC: Total lung capacity; TR: Tricuspid regurgitation; VAS:
visual analogue scale; VC: vital capacity
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Balkissoon 2006 Other - review of another manuscript
Bradley 1978 No suitable outcome
Bye 1985 No suitable outcome
Criner 1987 No suitable outcome
Cuvelier 2002 Patients already on home oxygen
Edvardsen 2007 Patients already on home oxygen
Evans 1986 No suitable outcome
Fujimoto 2002 No suitable outcome
Garrod 2000 Patients already on home oxygen
Gosselin 2004 No suitable outcome
King 1973 Mean PaO2 < 55 mmHg
Lane 1987 Not a randomised controlled trial
Leggett 1977 Mean PaO2 < 55 mmHg
No suitable outcome
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(Continued)
Light 1989 No suitable outcome
Liss 1988 Patients already on home oxygen
Lock 1992 Mean PaO2 < 55 mmHg
No placebo or control arm
Mannix 1992 No suitable outcome
Marques-Magallanes 1998 Mean PaO2 < 55 mmHg
No suitable outcome
Matsuzawa Japanese with no capacity for translation
Nasilowski 2008 Patients already on home oxygen
Nguyen 2008 Intervention not oxygen versus medical air
Noseda 1997 Intervention not oxygen versus medical air
O’Donnell 2001 Patients already on home oxygen
O’Driscoll 2003 Other - editorial
O’Driscoll 2007 No suitable outcome
O’Neill 2006 No suitable outcome
Ouyang 2006 Intervention not oxygen versus medical air
Peters 2006 Intervention not oxygen versus medical air
Raimondi 1970 No suitable outcome
Roberts 1996 Mean PaO2 < 55 mmHg
Patients already on home oxygen
Sandland 2008a Patients hypoxic at rest
Sandland 2008b Patients already on home oxygen or PRN oxygen
No dyspnoea outcome
Stein 1982 No suitable outcome
Stevenson 2004 No suitable outcome
Swinburn 1991 Mean PaO2 < 55 mmHg
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(Continued)
Vyas 1971 No suitable outcome
Waterhouse 1983 No suitable outcome
Wedzicha 2006 Other - editorial
PRN: Pro re nata or ’as needed’
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D A T A A N D A N A L Y S E S
Comparison 1. Oxygen versus air




participants Statistical method Effect size
1 Breathlessness - all trials 21 Std. Mean Difference (Random, 95% CI) -0.37 [-0.50, -0.24]
2 Breathlessness - subgroup
analysis - study focus
21 SMD (Random, 95% CI) Subtotals only
2.1 Studies with primary focus
= sensation
2 SMD (Random, 95% CI) -0.39 [-0.66, -0.12]
2.2 Studies with primary focus
= function
12 SMD (Random, 95% CI) -0.45 [-0.61, -0.30]
2.3 Studies with primary focus
= both
7 SMD (Random, 95% CI) -0.32 [-0.67, 0.03]
3 Breathlessness - subgroup
analysis - short burst or not
21 SMD (Random, 95% CI) Subtotals only
3.1 Studies not using
short-burst oxygen
17 SMD (Random, 95% CI) -0.46 [-0.59, -0.33]
3.2 Studies using short-burst
oxygen
4 SMD (Random, 95% CI) 0.01 [-0.26, 0.28]
4 Breathlessness - subgroup
analysis - saturation on exertion
21 SMD (Random, 95% CI) Subtotals only
4.1 Studies with exertional
desaturation
16 SMD (Random, 95% CI) -0.33 [-0.46, -0.20]
4.2 Studies with no exertional
desaturation
5 SMD (Random, 95% CI) -0.69 [-1.04, -0.34]
5 Breathlessness - subgroup
analysis - mean PaO2
21 SMD (Random, 95% CI) Subtotals only
5.1 Studies with mean PaO2
>= 70mmHg
15 SMD (Random, 95% CI) -0.42 [-0.60, -0.24]
5.2 Studies with mean PaO2
< 70mmHg
6 SMD (Random, 95% CI) -0.25 [-0.50, -0.00]
6 Breathlessness - sensitivity
analysis - quality
5 SMD (Random, 95% CI) -0.25 [-0.55, 0.06]
7 Breathlessness - sensitivity
analysis - no imputed quantities
6 SMD (Random, 95% CI) -0.36 [-0.64, -0.09]
8 Breathlessness - sensitivity - no
outliers
17 SMD (Random, 95% CI) -0.33 [-0.45, -0.22]
9 Breathlessness - sensitivity
analysis - no end exercise
17 SMD (Random, 95% CI) -0.37 [-0.54, -0.21]
10 Breathlessness - subgroup
analysis - short-burst or not -
post hoc - no outliers
17 SMD (Random, 95% CI) -0.33 [-0.45, -0.22]
10.1 Studies not using
short-burst oxygen
13 SMD (Random, 95% CI) -0.42 [-0.55, -0.28]
10.2 Studies using short-burst
oxygen
4 SMD (Random, 95% CI) -0.03 [-0.28, 0.22]
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11 Breathlessness - subgroup
analysis - study focus - post-hoc
- no outliers
17 SMD (Random, 95% CI) -0.33 [-0.45, -0.22]
11.1 Studies with primary
focus = function
10 SMD (Random, 95% CI) -0.42 [-0.58, -0.25]
11.2 Studies with primary
focus = sensation
2 SMD (Random, 95% CI) -0.39 [-0.66, -0.12]
11.3 Studies with primary
focus = both
5 SMD (Random, 95% CI) -0.15 [-0.43, 0.14]
12 Breathlessness - subgroup
analysis - saturation on exertion
- post-hoc - no outliers
17 SMD (Random, 95% CI) -0.33 [-0.45, -0.22]
12.1 Studies with exertional
desaturation
14 SMD (Random, 95% CI) -0.31 [-0.43, -0.18]
12.2 Studies with no
exertional desaturation
3 SMD (Random, 95% CI) -0.57 [-0.95, -0.19]
13 Breathlessness - subgroup
analysis - mean PaO2 -
post-hoc - no outliers
17 SMD (Random, 95% CI) -0.33 [-0.45, -0.22]
13.1 Studies with mean PaO2
>= 70mmHg
11 SMD (Random, 95% CI) -0.36 [-0.51, -0.22]
13.2 Studies with mean PaO2
< 70mmHg
6 SMD (Random, 95% CI) -0.25 [-0.50, -0.00]
14 Breathlessness - post-hoc - no
short-burst studies
17 SMD (Random, 95% CI) -0.46 [-0.59, -0.33]
15 Breathlessness - post-hoc -
subgroup analysis - saturation
on exertion - no short burst
17 SMD (Random, 95% CI) -0.46 [-0.59, -0.33]
15.1 Studies with exertional
desaturation
12 SMD (Random, 95% CI) -0.43 [-0.57, -0.29]
15.2 Studies with no
exertional desaturation
5 SMD (Random, 95% CI) -0.69 [-1.04, -0.34]
16 Breathlessness - post-hoc -
subgroup analysis - study focus
- no short-burst
17 SMD (Random, 95% CI) -0.53 [-0.69, -0.36]
16.1 Studies with primary
focus = sensation
1 SMD (Random, 95% CI) -0.42 [-0.71, -0.13]
16.2 Studies with primary
focus = function
12 SMD (Random, 95% CI) -0.53 [-0.74, -0.33]
16.3 Studies with primary
focus = both
4 SMD (Random, 95% CI) -0.67 [-1.19, -0.14]
17 Breathlessness - post-hoc -
subgroup analysis - mean PaO2
- no short-burst
17 SMD (Random, 95% CI) -0.46 [-0.58, -0.33]
17.1 Studies with mean PaO2
>= 70mmHg
13 SMD (Random, 95% CI) -0.47 [-0.62, -0.32]
17.2 Studies with mean PaO2
< 70mmHg
4 SMD (Random, 95% CI) -0.43 [-0.67, -0.19]
18 Breathlessness - post-hoc -
sensitivity analysis - quality -
no short-burst
4 SMD (Random, 95% CI) -0.25 [-0.59, 0.09]
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19 Breathlessness - post-hoc - no
outliers and no short-burst
13 SMD (Random, 95% CI) -0.42 [-0.55, -0.28]
20 Breathlessness - post-hoc -
sensitivity analysis - no imputed
quantities and no outliers
5 SMD (Random, 95% CI) -0.31 [-0.56, -0.05]
21 Breathlessness - post-hoc -
sensitivity analysis - no end
exercise and no outliers
13 SMD (Random, 95% CI) -0.31 [-0.44, -0.18]
22 Breathlessness - subgroup
analysis - dyspnoea measure
21 Std. Mean Difference (Random, 95% CI) -0.37 [-0.50, -0.24]
22.1 modified Borg 14 Std. Mean Difference (Random, 95% CI) -0.44 [-0.58, -0.29]
22.2 VAS 7 Std. Mean Difference (Random, 95% CI) -0.25 [-0.48, -0.02]
Analysis 1.1. Comparison 1 Oxygen versus air, Outcome 1 Breathlessness - all trials.
Review: Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease
Comparison: 1 Oxygen versus air











IV,Random,95% CI IV,Random,95% CI
Davidson 1988 -0.22 (0.35) 3.3 % -0.22 [ -0.91, 0.47 ]
Dean 1992 -1.4 (0.56) 1.4 % -1.40 [ -2.50, -0.30 ]
Eaton 2002 -0.42 (0.15) 12.7 % -0.42 [ -0.71, -0.13 ]
Emtner 2003 (group 1) -0.33 (0.38) 2.8 % -0.33 [ -1.07, 0.41 ]
Emtner 2003 (group 2) -0.5 (0.4) 2.6 % -0.50 [ -1.28, 0.28 ]
Eves 2006 -0.17 (0.45) 2.1 % -0.17 [ -1.05, 0.71 ]
Jolly 2001 (group 1) -1.31 (0.64) 1.0 % -1.31 [ -2.56, -0.06 ]
Jolly 2001 (group 2) -1.22 (0.56) 1.4 % -1.22 [ -2.32, -0.12 ]
Killen 2000 -0.25 (0.34) 3.5 % -0.25 [ -0.92, 0.42 ]
Knebel 2000 -0.13 (0.26) 5.5 % -0.13 [ -0.64, 0.38 ]
Kurihara 1989 -0.58 (0.24) 6.3 % -0.58 [ -1.05, -0.11 ]
Laude 2006 -0.44 (0.16) 11.6 % -0.44 [ -0.75, -0.13 ]
Lewis 2003 -0.1 (0.2) 8.4 % -0.10 [ -0.49, 0.29 ]
McDonald 1995 -0.4 (0.29) 4.6 % -0.40 [ -0.97, 0.17 ]
McKeon 1988a 0 (0.32) 3.9 % 0.0 [ -0.63, 0.63 ]
-2 -1 0 1 2
Favours oxygen Favours air
(Continued . . . )
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IV,Random,95% CI IV,Random,95% CI
Nandi 2003 0.17 (0.24) 6.3 % 0.17 [ -0.30, 0.64 ]
O’Donnell 1997 -0.44 (0.16) 11.6 % -0.44 [ -0.75, -0.13 ]
Rooyackers 1997 (group 1) -0.26 (0.41) 2.5 % -0.26 [ -1.06, 0.54 ]
Rooyackers 1997 (group 2) -0.33 (0.42) 2.3 % -0.33 [ -1.15, 0.49 ]
Somfay 2001 -1.43 (0.64) 1.0 % -1.43 [ -2.68, -0.18 ]
Woodcock 1981 -0.72 (0.27) 5.2 % -0.72 [ -1.25, -0.19 ]
Total (95% CI) 100.0 % -0.37 [ -0.50, -0.24 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 23.31, df = 20 (P = 0.27); I2 =14%
Test for overall effect: Z = 5.60 (P < 0.00001)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
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53Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.2. Comparison 1 Oxygen versus air, Outcome 2 Breathlessness - subgroup analysis - study focus.
Review: Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease
Comparison: 1 Oxygen versus air
Outcome: 2 Breathlessness - subgroup analysis - study focus
Study or subgroup SMD (SE) SMD Weight SMD
IV,Random,95% CI IV,Random,95% CI
1 Studies with primary focus = sensation
Eaton 2002 -0.42 (0.15) 83.7 % -0.42 [ -0.71, -0.13 ]
Killen 2000 -0.25 (0.34) 16.3 % -0.25 [ -0.92, 0.42 ]
Subtotal (95% CI) 100.0 % -0.39 [ -0.66, -0.12 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.21, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.86 (P = 0.0043)
2 Studies with primary focus = function
Davidson 1988 -0.22 (0.35) 5.4 % -0.22 [ -0.91, 0.47 ]
Dean 1992 -1.4 (0.56) 2.1 % -1.40 [ -2.50, -0.30 ]
Emtner 2003 (group 1) -0.33 (0.38) 4.6 % -0.33 [ -1.07, 0.41 ]
Emtner 2003 (group 2) -0.5 (0.4) 4.1 % -0.50 [ -1.28, 0.28 ]
Eves 2006 -0.17 (0.45) 3.3 % -0.17 [ -1.05, 0.71 ]
Kurihara 1989 -0.58 (0.24) 11.5 % -0.58 [ -1.05, -0.11 ]
Laude 2006 -0.44 (0.16) 25.9 % -0.44 [ -0.75, -0.13 ]
McDonald 1995 -0.4 (0.29) 7.9 % -0.40 [ -0.97, 0.17 ]
O’Donnell 1997 -0.44 (0.16) 25.9 % -0.44 [ -0.75, -0.13 ]
Rooyackers 1997 (group 1) -0.26 (0.41) 3.9 % -0.26 [ -1.06, 0.54 ]
Rooyackers 1997 (group 2) -0.33 (0.42) 3.8 % -0.33 [ -1.15, 0.49 ]
Somfay 2001 -1.43 (0.64) 1.6 % -1.43 [ -2.68, -0.18 ]
Subtotal (95% CI) 100.0 % -0.45 [ -0.61, -0.30 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 6.78, df = 11 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 5.59 (P < 0.00001)
3 Studies with primary focus = both
Jolly 2001 (group 1) -1.31 (0.64) 6.1 % -1.31 [ -2.56, -0.06 ]
Jolly 2001 (group 2) -1.22 (0.56) 7.5 % -1.22 [ -2.32, -0.12 ]
Knebel 2000 -0.25 (0.34) 14.1 % -0.25 [ -0.92, 0.42 ]
Lewis 2003 -0.1 (0.2) 21.2 % -0.10 [ -0.49, 0.29 ]
McKeon 1988a 0 (0.32) 14.9 % 0.0 [ -0.63, 0.63 ]
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Study or subgroup SMD (SE) SMD Weight SMD
IV,Random,95% CI IV,Random,95% CI
Nandi 2003 0.17 (0.24) 18.9 % 0.17 [ -0.30, 0.64 ]
Woodcock 1981 -0.72 (0.27) 17.3 % -0.72 [ -1.25, -0.19 ]
Subtotal (95% CI) 100.0 % -0.32 [ -0.67, 0.03 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 12.99, df = 6 (P = 0.04); I2 =54%
Test for overall effect: Z = 1.80 (P = 0.072)
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Analysis 1.3. Comparison 1 Oxygen versus air, Outcome 3 Breathlessness - subgroup analysis - short burst
or not.
Review: Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease
Comparison: 1 Oxygen versus air
Outcome: 3 Breathlessness - subgroup analysis - short burst or not
Study or subgroup SMD (SE) SMD Weight SMD
IV,Random,95% CI IV,Random,95% CI
1 Studies not using short-burst oxygen
Davidson 1988 -0.22 (0.35) 3.6 % -0.22 [ -0.91, 0.47 ]
Dean 1992 -1.4 (0.56) 1.4 % -1.40 [ -2.50, -0.30 ]
Eaton 2002 -0.42 (0.15) 19.4 % -0.42 [ -0.71, -0.13 ]
Emtner 2003 (group 1) -0.33 (0.38) 3.0 % -0.33 [ -1.07, 0.41 ]
Emtner 2003 (group 2) -0.5 (0.4) 2.7 % -0.50 [ -1.28, 0.28 ]
Eves 2006 -0.17 (0.45) 2.2 % -0.17 [ -1.05, 0.71 ]
Jolly 2001 (group 1) -1.31 (0.64) 1.1 % -1.31 [ -2.56, -0.06 ]
Jolly 2001 (group 2) -1.22 (0.56) 1.4 % -1.22 [ -2.32, -0.12 ]
Knebel 2000 -0.13 (0.26) 6.4 % -0.13 [ -0.64, 0.38 ]
Kurihara 1989 -0.58 (0.24) 7.6 % -0.58 [ -1.05, -0.11 ]
Laude 2006 -0.44 (0.16) 17.0 % -0.44 [ -0.75, -0.13 ]
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Study or subgroup SMD (SE) SMD Weight SMD
IV,Random,95% CI IV,Random,95% CI
McDonald 1995 -0.4 (0.29) 5.2 % -0.40 [ -0.97, 0.17 ]
O’Donnell 1997 -0.44 (0.16) 17.0 % -0.44 [ -0.75, -0.13 ]
Rooyackers 1997 (group 1) -0.26 (0.41) 2.6 % -0.26 [ -1.06, 0.54 ]
Rooyackers 1997 (group 2) -0.33 (0.42) 2.5 % -0.33 [ -1.15, 0.49 ]
Somfay 2001 -1.43 (0.64) 1.1 % -1.43 [ -2.68, -0.18 ]
Woodcock 1981 -0.71 (0.27) 6.0 % -0.71 [ -1.24, -0.18 ]
Subtotal (95% CI) 100.0 % -0.46 [ -0.59, -0.33 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 12.93, df = 16 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 7.00 (P < 0.00001)
2 Studies using short-burst oxygen
Killen 2000 -0.25 (34) 0.0 % -0.25 [ -66.89, 66.39 ]
Lewis 2003 -0.1 (0.2) 48.0 % -0.10 [ -0.49, 0.29 ]
McKeon 1988a 0 (0.32) 18.7 % 0.0 [ -0.63, 0.63 ]
Nandi 2003 0.17 (0.24) 33.3 % 0.17 [ -0.30, 0.64 ]
Subtotal (95% CI) 100.0 % 0.01 [ -0.26, 0.28 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.75, df = 3 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
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Analysis 1.4. Comparison 1 Oxygen versus air, Outcome 4 Breathlessness - subgroup analysis - saturation
on exertion.
Review: Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease
Comparison: 1 Oxygen versus air
Outcome: 4 Breathlessness - subgroup analysis - saturation on exertion
Study or subgroup SMD (SE) SMD Weight SMD
IV,Random,95% CI IV,Random,95% CI
1 Studies with exertional desaturation
Davidson 1988 -0.22 (0.35) 3.4 % -0.22 [ -0.91, 0.47 ]
Dean 1992 -1.4 (0.56) 1.4 % -1.40 [ -2.50, -0.30 ]
Eaton 2002 -0.42 (0.15) 15.8 % -0.42 [ -0.71, -0.13 ]
Eves 2006 -0.17 (0.45) 2.1 % -0.17 [ -1.05, 0.71 ]
Jolly 2001 (group 2) -1.22 (0.56) 1.4 % -1.22 [ -2.32, -0.12 ]
Killen 2000 -0.25 (0.34) 3.6 % -0.25 [ -0.92, 0.42 ]
Knebel 2000 -0.13 (0.26) 6.0 % -0.13 [ -0.64, 0.38 ]
Kurihara 1989 -0.58 (0.24) 7.0 % -0.58 [ -1.05, -0.11 ]
Laude 2006 -0.44 (0.16) 14.2 % -0.44 [ -0.75, -0.13 ]
Lewis 2003 -0.1 (0.2) 9.7 % -0.10 [ -0.49, 0.29 ]
McDonald 1995 -0.4 (0.29) 4.9 % -0.40 [ -0.97, 0.17 ]
McKeon 1988a 0 (0.32) 4.1 % 0.0 [ -0.63, 0.63 ]
Nandi 2003 0.17 (0.24) 7.0 % 0.17 [ -0.30, 0.64 ]
O’Donnell 1997 -0.44 (0.16) 14.2 % -0.44 [ -0.75, -0.13 ]
Rooyackers 1997 (group 1) -0.26 (0.41) 2.5 % -0.26 [ -1.06, 0.54 ]
Rooyackers 1997 (group 2) -0.33 (0.42) 2.4 % -0.33 [ -1.15, 0.49 ]
Subtotal (95% CI) 100.0 % -0.33 [ -0.46, -0.20 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 16.25, df = 15 (P = 0.37); I2 =8%
Test for overall effect: Z = 4.95 (P < 0.00001)
2 Studies with no exertional desaturation
Emtner 2003 (group 1) -0.33 (0.38) 21.8 % -0.33 [ -1.07, 0.41 ]
Emtner 2003 (group 2) -0.5 (0.4) 19.7 % -0.50 [ -1.28, 0.28 ]
Jolly 2001 (group 1) -1.31 (0.64) 7.7 % -1.31 [ -2.56, -0.06 ]
Somfay 2001 -1.43 (0.64) 7.7 % -1.43 [ -2.68, -0.18 ]
Woodcock 1981 -0.72 (0.27) 43.2 % -0.72 [ -1.25, -0.19 ]
Subtotal (95% CI) 100.0 % -0.69 [ -1.04, -0.34 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.41, df = 4 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 3.90 (P = 0.000097)
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Analysis 1.5. Comparison 1 Oxygen versus air, Outcome 5 Breathlessness - subgroup analysis - mean PaO2.
Review: Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease
Comparison: 1 Oxygen versus air
Outcome: 5 Breathlessness - subgroup analysis - mean PaO2
Study or subgroup SMD (SE) SMD Weight SMD
IV,Random,95% CI IV,Random,95% CI
1 Studies with mean PaO2 >= 70mmHg
Dean 1992 -1.4 (0.56) 2.5 % -1.40 [ -2.50, -0.30 ]
Eaton 2002 -0.42 (0.15) 16.0 % -0.42 [ -0.71, -0.13 ]
Emtner 2003 (group 1) -0.33 (0.38) 4.9 % -0.33 [ -1.07, 0.41 ]
Emtner 2003 (group 2) -0.5 (0.4) 4.5 % -0.50 [ -1.28, 0.28 ]
Jolly 2001 (group 1) -1.31 (0.64) 1.9 % -1.31 [ -2.56, -0.06 ]
Jolly 2001 (group 2) -1.22 (0.56) 2.5 % -1.22 [ -2.32, -0.12 ]
Killen 2000 -0.25 (0.34) 5.8 % -0.25 [ -0.92, 0.42 ]
Knebel 2000 -0.13 (0.26) 8.7 % -0.13 [ -0.64, 0.38 ]
Lewis 2003 0.1 (0.2) 12.1 % 0.10 [ -0.29, 0.49 ]
McDonald 1995 -0.4 (0.29) 7.4 % -0.40 [ -0.97, 0.17 ]
O’Donnell 1997 -0.44 (0.16) 15.1 % -0.44 [ -0.75, -0.13 ]
Rooyackers 1997 (group 1) -0.26 (0.41) 4.3 % -0.26 [ -1.06, 0.54 ]
Rooyackers 1997 (group 2) -0.33 (0.42) 4.1 % -0.33 [ -1.15, 0.49 ]
Somfay 2001 -1.43 (0.64) 1.9 % -1.43 [ -2.68, -0.18 ]
Woodcock 1981 -0.72 (0.27) 8.2 % -0.72 [ -1.25, -0.19 ]
Subtotal (95% CI) 100.0 % -0.42 [ -0.60, -0.24 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 19.18, df = 14 (P = 0.16); I2 =27%
Test for overall effect: Z = 4.52 (P < 0.00001)
2 Studies with mean PaO2 < 70mmHg
Davidson 1988 -0.22 (0.35) 10.9 % -0.22 [ -0.91, 0.47 ]
Eves 2006 -0.17 (0.45) 7.1 % -0.17 [ -1.05, 0.71 ]
Kurihara 1989 -0.58 (0.24) 19.2 % -0.58 [ -1.05, -0.11 ]
Laude 2006 -0.44 (0.16) 31.0 % -0.44 [ -0.75, -0.13 ]
-4 -2 0 2 4
Favours oxygen Favours air
(Continued . . . )
58Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup SMD (SE) SMD Weight SMD
IV,Random,95% CI IV,Random,95% CI
McKeon 1988a 0 (0.32) 12.6 % 0.0 [ -0.63, 0.63 ]
Nandi 2003 0.17 (0.24) 19.2 % 0.17 [ -0.30, 0.64 ]
Subtotal (95% CI) 100.0 % -0.25 [ -0.50, 0.00 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 6.93, df = 5 (P = 0.23); I2 =28%
Test for overall effect: Z = 1.98 (P = 0.048)
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Analysis 1.6. Comparison 1 Oxygen versus air, Outcome 6 Breathlessness - sensitivity analysis - quality.
Review: Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease
Comparison: 1 Oxygen versus air
Outcome: 6 Breathlessness - sensitivity analysis - quality
Study or subgroup SMD (SE) SMD Weight SMD
IV,Random,95% CI IV,Random,95% CI
Emtner 2003 (group 1) -0.33 (0.38) 16.7 % -0.33 [ -1.07, 0.41 ]
Emtner 2003 (group 2) -0.5 (0.4) 15.0 % -0.50 [ -1.28, 0.28 ]
Eves 2006 -0.17 (0.45) 11.9 % -0.17 [ -1.05, 0.71 ]
Killen 2000 -0.25 (0.34) 20.8 % -0.25 [ -0.92, 0.42 ]
Knebel 2000 -0.13 (0.26) 35.6 % -0.13 [ -0.64, 0.38 ]
Total (95% CI) 100.0 % -0.25 [ -0.55, 0.06 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.68, df = 4 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.60 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Oxygen versus air, Outcome 7 Breathlessness - sensitivity analysis - no imputed
quantities.
Review: Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease
Comparison: 1 Oxygen versus air
Outcome: 7 Breathlessness - sensitivity analysis - no imputed quantities
Study or subgroup SMD (SE) SMD Weight SMD
IV,Random,95% CI IV,Random,95% CI
Dean 1992 -1.4 (0.56) 5.3 % -1.40 [ -2.50, -0.30 ]
Eaton 2002 -0.42 (0.15) 22.8 % -0.42 [ -0.71, -0.13 ]
Lewis 2003 -0.1 (0.2) 19.0 % -0.10 [ -0.49, 0.29 ]
Nandi 2003 0.17 (0.24) 16.3 % 0.17 [ -0.30, 0.64 ]
O’Donnell 1997 -0.44 (0.16) 22.1 % -0.44 [ -0.75, -0.13 ]
Woodcock 1981 -0.72 (0.27) 14.5 % -0.72 [ -1.25, -0.19 ]
Total (95% CI) 100.0 % -0.36 [ -0.64, -0.09 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 12.18, df = 5 (P = 0.03); I2 =59%
Test for overall effect: Z = 2.56 (P = 0.010)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Oxygen versus air, Outcome 8 Breathlessness - sensitivity - no outliers.
Review: Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease
Comparison: 1 Oxygen versus air
Outcome: 8 Breathlessness - sensitivity - no outliers
Study or subgroup SMD (SE) SMD Weight SMD
IV,Random,95% CI IV,Random,95% CI
Davidson 1988 -0.22 (0.35) 2.9 % -0.22 [ -0.91, 0.47 ]
Eaton 2002 -0.42 (0.15) 15.9 % -0.42 [ -0.71, -0.13 ]
Emtner 2003 (group 1) -0.33 (0.38) 2.5 % -0.33 [ -1.07, 0.41 ]
Emtner 2003 (group 2) -0.5 (0.4) 2.2 % -0.50 [ -1.28, 0.28 ]
Eves 2006 -0.17 (0.45) 1.8 % -0.17 [ -1.05, 0.71 ]
Killen 2000 -0.25 (0.34) 3.1 % -0.25 [ -0.92, 0.42 ]
Knebel 2000 -0.13 (0.26) 5.3 % -0.13 [ -0.64, 0.38 ]
Kurihara 1989 -0.58 (0.24) 6.2 % -0.58 [ -1.05, -0.11 ]
Laude 2006 -0.44 (0.16) 14.0 % -0.44 [ -0.75, -0.13 ]
Lewis 2003 -0.1 (0.2) 9.0 % -0.10 [ -0.49, 0.29 ]
McDonald 1995 -0.4 (0.29) 4.3 % -0.40 [ -0.97, 0.17 ]
McKeon 1988a 0 (0.32) 3.5 % 0.0 [ -0.63, 0.63 ]
Nandi 2003 0.17 (0.24) 6.2 % 0.17 [ -0.30, 0.64 ]
O’Donnell 1997 -0.44 (0.16) 14.0 % -0.44 [ -0.75, -0.13 ]
Rooyackers 1997 (group 1) -0.26 (0.41) 2.1 % -0.26 [ -1.06, 0.54 ]
Rooyackers 1997 (group 2) -0.33 (0.42) 2.0 % -0.33 [ -1.15, 0.49 ]
Woodcock 1981 -0.72 (0.27) 4.9 % -0.72 [ -1.25, -0.19 ]
Total (95% CI) 100.0 % -0.33 [ -0.45, -0.22 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 12.34, df = 16 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 5.56 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Oxygen versus air, Outcome 9 Breathlessness - sensitivity analysis - no end
exercise.
Review: Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease
Comparison: 1 Oxygen versus air
Outcome: 9 Breathlessness - sensitivity analysis - no end exercise
Study or subgroup SMD (SE) SMD Weight SMD
IV,Random,95% CI IV,Random,95% CI
Davidson 1988 -0.22 (0.35) 4.6 % -0.22 [ -0.91, 0.47 ]
Dean 1992 -1.4 (0.56) 2.1 % -1.40 [ -2.50, -0.30 ]
Eaton 2002 -0.42 (0.15) 13.0 % -0.42 [ -0.71, -0.13 ]
Jolly 2001 (group 1) -1.31 (0.64) 1.6 % -1.31 [ -2.56, -0.06 ]
Jolly 2001 (group 2) -1.22 (0.56) 2.1 % -1.22 [ -2.32, -0.12 ]
Killen 2000 -0.25 (0.34) 4.8 % -0.25 [ -0.92, 0.42 ]
Knebel 2000 -0.13 (0.26) 7.1 % -0.13 [ -0.64, 0.38 ]
Kurihara 1989 -0.58 (0.24) 7.9 % -0.58 [ -1.05, -0.11 ]
Lewis 2003 -0.1 (0.2) 9.8 % -0.10 [ -0.49, 0.29 ]
McDonald 1995 -0.4 (0.29) 6.1 % -0.40 [ -0.97, 0.17 ]
McKeon 1988a 0 (0.32) 5.3 % 0.0 [ -0.63, 0.63 ]
Nandi 2003 0.17 (0.24) 7.9 % 0.17 [ -0.30, 0.64 ]
O’Donnell 1997 -0.44 (0.16) 12.3 % -0.44 [ -0.75, -0.13 ]
Rooyackers 1997 (group 1) -0.26 (0.41) 3.6 % -0.26 [ -1.06, 0.54 ]
Rooyackers 1997 (group 2) -0.33 (0.42) 3.4 % -0.33 [ -1.15, 0.49 ]
Somfay 2001 -1.43 (0.64) 1.6 % -1.43 [ -2.68, -0.18 ]
Woodcock 1981 -0.72 (0.27) 6.8 % -0.72 [ -1.25, -0.19 ]
Total (95% CI) 100.0 % -0.37 [ -0.54, -0.21 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 22.80, df = 16 (P = 0.12); I2 =30%
Test for overall effect: Z = 4.43 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Oxygen versus air, Outcome 10 Breathlessness - subgroup analysis - short-
burst or not - post hoc - no outliers.
Review: Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease
Comparison: 1 Oxygen versus air
Outcome: 10 Breathlessness - subgroup analysis - short-burst or not - post hoc - no outliers
Study or subgroup SMD (SE) SMD Weight SMD
IV,Random,95% CI IV,Random,95% CI
1 Studies not using short-burst oxygen
Davidson 1988 -0.22 (0.35) 2.9 % -0.22 [ -0.91, 0.47 ]
Eaton 2002 -0.42 (0.15) 15.9 % -0.42 [ -0.71, -0.13 ]
Emtner 2003 (group 1) -0.33 (0.38) 2.5 % -0.33 [ -1.07, 0.41 ]
Emtner 2003 (group 2) -0.5 (0.4) 2.2 % -0.50 [ -1.28, 0.28 ]
Eves 2006 -0.17 (0.45) 1.8 % -0.17 [ -1.05, 0.71 ]
Knebel 2000 -0.13 (0.26) 5.3 % -0.13 [ -0.64, 0.38 ]
Kurihara 1989 -0.58 (0.24) 6.2 % -0.58 [ -1.05, -0.11 ]
Laude 2006 -0.44 (0.16) 14.0 % -0.44 [ -0.75, -0.13 ]
McDonald 1995 -0.4 (0.29) 4.3 % -0.40 [ -0.97, 0.17 ]
O’Donnell 1997 -0.44 (0.16) 14.0 % -0.44 [ -0.75, -0.13 ]
Rooyackers 1997 (group 1) -0.26 (0.41) 2.1 % -0.26 [ -1.06, 0.54 ]
Rooyackers 1997 (group 2) -0.33 (0.42) 2.0 % -0.33 [ -1.15, 0.49 ]
Woodcock 1981 -0.72 (0.27) 4.9 % -0.72 [ -1.25, -0.19 ]
Subtotal (95% CI) 78.2 % -0.42 [ -0.55, -0.28 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.89, df = 12 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 6.17 (P < 0.00001)
2 Studies using short-burst oxygen
Killen 2000 -0.25 (0.34) 3.1 % -0.25 [ -0.92, 0.42 ]
Lewis 2003 -0.1 (0.2) 9.0 % -0.10 [ -0.49, 0.29 ]
McKeon 1988a 0 (0.32) 3.5 % 0.0 [ -0.63, 0.63 ]
Nandi 2003 0.17 (0.24) 6.2 % 0.17 [ -0.30, 0.64 ]
Subtotal (95% CI) 21.8 % -0.03 [ -0.28, 0.22 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.24, df = 3 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.83)
Total (95% CI) 100.0 % -0.33 [ -0.45, -0.22 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 12.34, df = 16 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 5.56 (P < 0.00001)
Test for subgroup differences: Chi2 = 7.21, df = 1 (P = 0.01), I2 =86%
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Analysis 1.11. Comparison 1 Oxygen versus air, Outcome 11 Breathlessness - subgroup analysis - study
focus - post-hoc - no outliers.
Review: Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease
Comparison: 1 Oxygen versus air
Outcome: 11 Breathlessness - subgroup analysis - study focus - post-hoc - no outliers
Study or subgroup SMD (SE) SMD Weight SMD
IV,Random,95% CI IV,Random,95% CI
1 Studies with primary focus = function
Davidson 1988 -0.22 (0.35) 2.9 % -0.22 [ -0.91, 0.47 ]
Emtner 2003 (group 1) -0.33 (0.38) 2.5 % -0.33 [ -1.07, 0.41 ]
Emtner 2003 (group 2) -0.5 (0.4) 2.2 % -0.50 [ -1.28, 0.28 ]
Eves 2006 -0.17 (0.45) 1.8 % -0.17 [ -1.05, 0.71 ]
Kurihara 1989 -0.58 (0.24) 6.2 % -0.58 [ -1.05, -0.11 ]
Laude 2006 -0.44 (0.16) 14.0 % -0.44 [ -0.75, -0.13 ]
McDonald 1995 -0.4 (0.29) 4.3 % -0.40 [ -0.97, 0.17 ]
O’Donnell 1997 -0.44 (0.16) 14.0 % -0.44 [ -0.75, -0.13 ]
Rooyackers 1997 (group 1) -0.26 (0.41) 2.1 % -0.26 [ -1.06, 0.54 ]
Rooyackers 1997 (group 2) -0.33 (0.42) 2.0 % -0.33 [ -1.15, 0.49 ]
Subtotal (95% CI) 52.1 % -0.42 [ -0.58, -0.25 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.41, df = 9 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 5.03 (P < 0.00001)
2 Studies with primary focus = sensation
Eaton 2002 -0.42 (0.15) 15.9 % -0.42 [ -0.71, -0.13 ]
Killen 2000 -0.25 (0.34) 3.1 % -0.25 [ -0.92, 0.42 ]
Subtotal (95% CI) 19.0 % -0.39 [ -0.66, -0.12 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.21, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.86 (P = 0.0043)
3 Studies with primary focus = both
Knebel 2000 -0.13 (0.26) 5.3 % -0.13 [ -0.64, 0.38 ]
Lewis 2003 -0.1 (0.2) 9.0 % -0.10 [ -0.49, 0.29 ]
McKeon 1988a 0 (0.32) 3.5 % 0.0 [ -0.63, 0.63 ]
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Study or subgroup SMD (SE) SMD Weight SMD
IV,Random,95% CI IV,Random,95% CI
Nandi 2003 0.17 (0.24) 6.2 % 0.17 [ -0.30, 0.64 ]
Woodcock 1981 -0.72 (0.27) 4.9 % -0.72 [ -1.25, -0.19 ]
Subtotal (95% CI) 28.9 % -0.15 [ -0.43, 0.14 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 6.52, df = 4 (P = 0.16); I2 =39%
Test for overall effect: Z = 1.02 (P = 0.31)
Total (95% CI) 100.0 % -0.33 [ -0.45, -0.22 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 12.34, df = 16 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 5.56 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.69, df = 2 (P = 0.26), I2 =26%
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Analysis 1.12. Comparison 1 Oxygen versus air, Outcome 12 Breathlessness - subgroup analysis - saturation
on exertion - post-hoc - no outliers.
Review: Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease
Comparison: 1 Oxygen versus air
Outcome: 12 Breathlessness - subgroup analysis - saturation on exertion - post-hoc - no outliers
Study or subgroup SMD (SE) SMD Weight SMD
IV,Random,95% CI IV,Random,95% CI
1 Studies with exertional desaturation
Davidson 1988 -0.22 (0.35) 2.9 % -0.22 [ -0.91, 0.47 ]
Eaton 2002 -0.42 (0.15) 15.9 % -0.42 [ -0.71, -0.13 ]
Eves 2006 -0.17 (0.45) 1.8 % -0.17 [ -1.05, 0.71 ]
Killen 2000 -0.25 (0.34) 3.1 % -0.25 [ -0.92, 0.42 ]
Knebel 2000 -0.13 (0.26) 5.3 % -0.13 [ -0.64, 0.38 ]
Kurihara 1989 -0.58 (0.24) 6.2 % -0.58 [ -1.05, -0.11 ]
Laude 2006 -0.44 (0.16) 14.0 % -0.44 [ -0.75, -0.13 ]
Lewis 2003 -0.1 (0.2) 9.0 % -0.10 [ -0.49, 0.29 ]
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Study or subgroup SMD (SE) SMD Weight SMD
IV,Random,95% CI IV,Random,95% CI
McDonald 1995 -0.4 (0.29) 4.3 % -0.40 [ -0.97, 0.17 ]
McKeon 1988a 0 (0.32) 3.5 % 0.0 [ -0.63, 0.63 ]
Nandi 2003 0.17 (0.24) 6.2 % 0.17 [ -0.30, 0.64 ]
O’Donnell 1997 -0.44 (0.16) 14.0 % -0.44 [ -0.75, -0.13 ]
Rooyackers 1997 (group 1) -0.26 (0.41) 2.1 % -0.26 [ -1.06, 0.54 ]
Rooyackers 1997 (group 2) -0.33 (0.42) 2.0 % -0.33 [ -1.15, 0.49 ]
Subtotal (95% CI) 90.4 % -0.31 [ -0.43, -0.18 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 9.95, df = 13 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 4.88 (P < 0.00001)
2 Studies with no exertional desaturation
Emtner 2003 (group 1) -0.33 (0.38) 2.5 % -0.33 [ -1.07, 0.41 ]
Emtner 2003 (group 2) -0.5 (0.4) 2.2 % -0.50 [ -1.28, 0.28 ]
Woodcock 1981 -0.72 (0.27) 4.9 % -0.72 [ -1.25, -0.19 ]
Subtotal (95% CI) 9.6 % -0.57 [ -0.95, -0.19 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.74, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 2.95 (P = 0.0032)
Total (95% CI) 100.0 % -0.33 [ -0.45, -0.22 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 12.34, df = 16 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 5.56 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.65, df = 1 (P = 0.20), I2 =40%
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Analysis 1.13. Comparison 1 Oxygen versus air, Outcome 13 Breathlessness - subgroup analysis - mean
PaO2 - post-hoc - no outliers.
Review: Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease
Comparison: 1 Oxygen versus air
Outcome: 13 Breathlessness - subgroup analysis - mean PaO2 - post-hoc - no outliers
Study or subgroup SMD (SE) SMD Weight SMD
IV,Random,95% CI IV,Random,95% CI
1 Studies with mean PaO2 >= 70mmHg
Eaton 2002 -0.42 (0.15) 15.9 % -0.42 [ -0.71, -0.13 ]
Emtner 2003 (group 1) -0.33 (0.38) 2.5 % -0.33 [ -1.07, 0.41 ]
Emtner 2003 (group 2) -0.5 (0.4) 2.2 % -0.50 [ -1.28, 0.28 ]
Killen 2000 -0.25 (0.34) 3.1 % -0.25 [ -0.92, 0.42 ]
Knebel 2000 -0.13 (0.26) 5.3 % -0.13 [ -0.64, 0.38 ]
Lewis 2003 -0.1 (0.2) 9.0 % -0.10 [ -0.49, 0.29 ]
McDonald 1995 -0.4 (0.29) 4.3 % -0.40 [ -0.97, 0.17 ]
O’Donnell 1997 -0.44 (0.16) 14.0 % -0.44 [ -0.75, -0.13 ]
Rooyackers 1997 (group 1) -0.26 (0.41) 2.1 % -0.26 [ -1.06, 0.54 ]
Rooyackers 1997 (group 2) -0.33 (0.42) 2.0 % -0.33 [ -1.15, 0.49 ]
Woodcock 1981 -0.72 (0.27) 4.9 % -0.72 [ -1.25, -0.19 ]
Subtotal (95% CI) 65.4 % -0.36 [ -0.51, -0.22 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.98, df = 10 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 4.88 (P < 0.00001)
2 Studies with mean PaO2 < 70mmHg
Davidson 1988 -0.22 (0.35) 2.9 % -0.22 [ -0.91, 0.47 ]
Eves 2006 -0.17 (0.45) 1.8 % -0.17 [ -1.05, 0.71 ]
Kurihara 1989 -0.58 (0.24) 6.2 % -0.58 [ -1.05, -0.11 ]
Laude 2006 -0.44 (0.16) 14.0 % -0.44 [ -0.75, -0.13 ]
McKeon 1988a 0 (0.32) 3.5 % 0.0 [ -0.63, 0.63 ]
Nandi 2003 0.17 (0.24) 6.2 % 0.17 [ -0.30, 0.64 ]
Subtotal (95% CI) 34.6 % -0.25 [ -0.50, 0.00 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 6.93, df = 5 (P = 0.23); I2 =28%
Test for overall effect: Z = 1.98 (P = 0.048)
Total (95% CI) 100.0 % -0.33 [ -0.45, -0.22 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 12.34, df = 16 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 5.56 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.56, df = 1 (P = 0.45), I2 =0.0%
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Analysis 1.14. Comparison 1 Oxygen versus air, Outcome 14 Breathlessness - post-hoc - no short-burst
studies.
Review: Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease
Comparison: 1 Oxygen versus air
Outcome: 14 Breathlessness - post-hoc - no short-burst studies
Study or subgroup SMD (SE) SMD Weight SMD
IV,Random,95% CI IV,Random,95% CI
Davidson 1988 -0.22 (0.35) 3.6 % -0.22 [ -0.91, 0.47 ]
Dean 1992 -1.4 (0.56) 1.4 % -1.40 [ -2.50, -0.30 ]
Eaton 2002 -0.42 (0.15) 19.4 % -0.42 [ -0.71, -0.13 ]
Emtner 2003 (group 1) -0.33 (0.38) 3.0 % -0.33 [ -1.07, 0.41 ]
Emtner 2003 (group 2) -0.5 (0.4) 2.7 % -0.50 [ -1.28, 0.28 ]
Eves 2006 -0.17 (0.45) 2.2 % -0.17 [ -1.05, 0.71 ]
Jolly 2001 (group 1) -1.31 (0.64) 1.1 % -1.31 [ -2.56, -0.06 ]
Jolly 2001 (group 2) -1.22 (0.56) 1.4 % -1.22 [ -2.32, -0.12 ]
Knebel 2000 -0.13 (0.26) 6.4 % -0.13 [ -0.64, 0.38 ]
Kurihara 1989 -0.58 (0.24) 7.6 % -0.58 [ -1.05, -0.11 ]
Laude 2006 -0.44 (0.16) 17.0 % -0.44 [ -0.75, -0.13 ]
McDonald 1995 -0.4 (0.29) 5.2 % -0.40 [ -0.97, 0.17 ]
O’Donnell 1997 -0.44 (0.16) 17.0 % -0.44 [ -0.75, -0.13 ]
Rooyackers 1997 (group 1) -0.26 (0.41) 2.6 % -0.26 [ -1.06, 0.54 ]
Rooyackers 1997 (group 2) -0.33 (0.42) 2.5 % -0.33 [ -1.15, 0.49 ]
Somfay 2001 -1.43 (0.64) 1.1 % -1.43 [ -2.68, -0.18 ]
Woodcock 1981 -0.72 (0.27) 6.0 % -0.72 [ -1.25, -0.19 ]
Total (95% CI) 100.0 % -0.46 [ -0.59, -0.33 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 13.00, df = 16 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 7.01 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Oxygen versus air, Outcome 15 Breathlessness - post-hoc - subgroup analysis -
saturation on exertion - no short burst.
Review: Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease
Comparison: 1 Oxygen versus air
Outcome: 15 Breathlessness - post-hoc - subgroup analysis - saturation on exertion - no short burst
Study or subgroup SMD (SE) SMD Weight SMD
IV,Random,95% CI IV,Random,95% CI
1 Studies with exertional desaturation
Davidson 1988 -0.22 (0.35) 3.6 % -0.22 [ -0.91, 0.47 ]
Dean 1992 -1.4 (0.56) 1.4 % -1.40 [ -2.50, -0.30 ]
Eaton 2002 -0.42 (0.15) 19.4 % -0.42 [ -0.71, -0.13 ]
Eves 2006 -0.17 (0.45) 2.2 % -0.17 [ -1.05, 0.71 ]
Jolly 2001 (group 2) -1.22 (0.56) 1.4 % -1.22 [ -2.32, -0.12 ]
Knebel 2000 -0.13 (0.26) 6.4 % -0.13 [ -0.64, 0.38 ]
Kurihara 1989 -0.58 (0.24) 7.6 % -0.58 [ -1.05, -0.11 ]
Laude 2006 -0.44 (0.16) 17.0 % -0.44 [ -0.75, -0.13 ]
McDonald 1995 -0.4 (0.29) 5.2 % -0.40 [ -0.97, 0.17 ]
O’Donnell 1997 -0.44 (0.16) 17.0 % -0.44 [ -0.75, -0.13 ]
Rooyackers 1997 (group 1) -0.26 (0.41) 2.6 % -0.26 [ -1.06, 0.54 ]
Rooyackers 1997 (group 2) -0.33 (0.42) 2.5 % -0.33 [ -1.15, 0.49 ]
Subtotal (95% CI) 86.2 % -0.43 [ -0.57, -0.29 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 7.65, df = 11 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 5.99 (P < 0.00001)
2 Studies with no exertional desaturation
Emtner 2003 (group 1) -0.33 (0.38) 3.0 % -0.33 [ -1.07, 0.41 ]
Emtner 2003 (group 2) -0.5 (0.4) 2.7 % -0.50 [ -1.28, 0.28 ]
Jolly 2001 (group 1) -1.31 (0.64) 1.1 % -1.31 [ -2.56, -0.06 ]
Somfay 2001 -1.43 (0.64) 1.1 % -1.43 [ -2.68, -0.18 ]
Woodcock 1981 -0.72 (0.27) 6.0 % -0.72 [ -1.25, -0.19 ]
Subtotal (95% CI) 13.8 % -0.69 [ -1.04, -0.34 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.41, df = 4 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 3.90 (P = 0.000097)
Total (95% CI) 100.0 % -0.46 [ -0.59, -0.33 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 13.00, df = 16 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 7.01 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.93, df = 1 (P = 0.16), I2 =48%
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Analysis 1.16. Comparison 1 Oxygen versus air, Outcome 16 Breathlessness - post-hoc - subgroup analysis -
study focus - no short-burst.
Review: Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease
Comparison: 1 Oxygen versus air
Outcome: 16 Breathlessness - post-hoc - subgroup analysis - study focus - no short-burst
Study or subgroup SMD (SE) SMD Weight SMD
IV,Random,95% CI IV,Random,95% CI
1 Studies with primary focus = sensation
Eaton 2002 -0.42 (0.15) 12.9 % -0.42 [ -0.71, -0.13 ]
Subtotal (95% CI) 12.9 % -0.42 [ -0.71, -0.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.80 (P = 0.0051)
2 Studies with primary focus = function
Davidson 1988 -0.22 (0.35) 4.6 % -0.22 [ -0.91, 0.47 ]
Dean 1992 -1.4 (0.56) 2.1 % -1.40 [ -2.50, -0.30 ]
Emtner 2003 (group 1) -0.33 (0.38) 4.0 % -0.33 [ -1.07, 0.41 ]
Emtner 2003 (group 2) -0.5 (0.4) 3.7 % -0.50 [ -1.28, 0.28 ]
Eves 2006 -0.17 (0.45) 3.0 % -0.17 [ -1.05, 0.71 ]
Kurihara 1989 -0.58 (0.24) 7.9 % -0.58 [ -1.05, -0.11 ]
Laude 2006 -0.44 (0.16) 12.2 % -0.44 [ -0.75, -0.13 ]
McDonald 1995 -0.4 (0.29) 6.1 % -0.40 [ -0.97, 0.17 ]
O’Donnell 1997 -0.44 (0.16) 12.2 % -0.44 [ -0.75, -0.13 ]
Rooyackers 1997 (group 1) -0.26 (0.41) 3.6 % -0.26 [ -1.06, 0.54 ]
Rooyackers 1997 (group 2) -0.33 (0.42) 3.4 % -0.33 [ -1.15, 0.49 ]
Somfay 2001 -1.43 (0.27) 6.8 % -1.43 [ -1.96, -0.90 ]
Subtotal (95% CI) 69.6 % -0.53 [ -0.74, -0.33 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 16.76, df = 11 (P = 0.12); I2 =34%
Test for overall effect: Z = 5.04 (P < 0.00001)
3 Studies with primary focus = both
Jolly 2001 (group 1) -1.31 (0.64) 1.6 % -1.31 [ -2.56, -0.06 ]
Jolly 2001 (group 2) -1.22 (0.56) 2.1 % -1.22 [ -2.32, -0.12 ]
Knebel 2000 -0.13 (0.26) 7.1 % -0.13 [ -0.64, 0.38 ]
Woodcock 1981 -0.72 (0.27) 6.8 % -0.72 [ -1.25, -0.19 ]
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Study or subgroup SMD (SE) SMD Weight SMD
IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 17.5 % -0.67 [ -1.19, -0.14 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 5.85, df = 3 (P = 0.12); I2 =49%
Test for overall effect: Z = 2.50 (P = 0.013)
Total (95% CI) 100.0 % -0.53 [ -0.69, -0.36 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 23.06, df = 16 (P = 0.11); I2 =31%
Test for overall effect: Z = 6.26 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.75, df = 2 (P = 0.69), I2 =0.0%
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Analysis 1.17. Comparison 1 Oxygen versus air, Outcome 17 Breathlessness - post-hoc - subgroup analysis -
mean PaO2 - no short-burst.
Review: Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease
Comparison: 1 Oxygen versus air
Outcome: 17 Breathlessness - post-hoc - subgroup analysis - mean PaO2 - no short-burst
Study or subgroup SMD (SE) SMD Weight SMD
IV,Random,95% CI IV,Random,95% CI
1 Studies with mean PaO2 >= 70mmHg
Dean 1992 -1.4 (0.56) 1.3 % -1.40 [ -2.50, -0.30 ]
Eaton 2002 -0.42 (0.15) 17.9 % -0.42 [ -0.71, -0.13 ]
Emtner 2003 (group 1) -0.33 (0.38) 2.8 % -0.33 [ -1.07, 0.41 ]
Emtner 2003 (group 2) -0.5 (0.4) 2.5 % -0.50 [ -1.28, 0.28 ]
Jolly 2001 (group 1) -1.31 (0.64) 1.0 % -1.31 [ -2.56, -0.06 ]
Jolly 2001 (group 2) -1.22 (0.56) 1.3 % -1.22 [ -2.32, -0.12 ]
Knebel 2000 -0.13 (0.26) 6.0 % -0.13 [ -0.64, 0.38 ]
McDonald 1995 -0.4 (0.18) 12.4 % -0.40 [ -0.75, -0.05 ]
O’Donnell 1997 -0.44 (0.16) 15.7 % -0.44 [ -0.75, -0.13 ]
Rooyackers 1997 (group 1) -0.26 (0.41) 2.4 % -0.26 [ -1.06, 0.54 ]
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Study or subgroup SMD (SE) SMD Weight SMD
IV,Random,95% CI IV,Random,95% CI
Rooyackers 1997 (group 2) -0.33 (0.42) 2.3 % -0.33 [ -1.15, 0.49 ]
Somfay 2001 -1.43 (0.64) 1.0 % -1.43 [ -2.68, -0.18 ]
Woodcock 1981 -0.72 (0.27) 5.5 % -0.72 [ -1.25, -0.19 ]
Subtotal (95% CI) 72.0 % -0.47 [ -0.62, -0.32 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 11.90, df = 12 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 6.27 (P < 0.00001)
2 Studies with mean PaO2 < 70mmHg
Davidson 1988 -0.22 (0.35) 3.3 % -0.22 [ -0.91, 0.47 ]
Eves 2006 -0.17 (0.45) 2.0 % -0.17 [ -1.05, 0.71 ]
Kurihara 1989 -0.58 (0.24) 7.0 % -0.58 [ -1.05, -0.11 ]
Laude 2006 -0.44 (0.16) 15.7 % -0.44 [ -0.75, -0.13 ]
Subtotal (95% CI) 28.0 % -0.43 [ -0.67, -0.19 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.09, df = 3 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 3.59 (P = 0.00034)
Total (95% CI) 100.0 % -0.46 [ -0.58, -0.33 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 13.07, df = 16 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 7.22 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.08, df = 1 (P = 0.78), I2 =0.0%
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Analysis 1.18. Comparison 1 Oxygen versus air, Outcome 18 Breathlessness - post-hoc - sensitivity analysis -
quality - no short-burst.
Review: Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease
Comparison: 1 Oxygen versus air
Outcome: 18 Breathlessness - post-hoc - sensitivity analysis - quality - no short-burst
Study or subgroup SMD (SE) SMD Weight SMD
IV,Random,95% CI IV,Random,95% CI
Emtner 2003 (group 1) -0.33 (0.38) 21.0 % -0.33 [ -1.07, 0.41 ]
Emtner 2003 (group 2) -0.5 (0.4) 19.0 % -0.50 [ -1.28, 0.28 ]
Eves 2006 -0.17 (0.45) 15.0 % -0.17 [ -1.05, 0.71 ]
Knebel 2000 -0.13 (0.26) 45.0 % -0.13 [ -0.64, 0.38 ]
Total (95% CI) 100.0 % -0.25 [ -0.59, 0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.68, df = 3 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.42 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 1.19. Comparison 1 Oxygen versus air, Outcome 19 Breathlessness - post-hoc - no outliers and no
short-burst.
Review: Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease
Comparison: 1 Oxygen versus air
Outcome: 19 Breathlessness - post-hoc - no outliers and no short-burst
Study or subgroup SMD (SE) SMD Weight SMD
IV,Random,95% CI IV,Random,95% CI
Davidson 1988 -0.22 (0.35) 3.7 % -0.22 [ -0.91, 0.47 ]
Eaton 2002 -0.42 (0.15) 20.4 % -0.42 [ -0.71, -0.13 ]
Emtner 2003 (group 1) -0.33 (0.38) 3.2 % -0.33 [ -1.07, 0.41 ]
Emtner 2003 (group 2) -0.5 (0.4) 2.9 % -0.50 [ -1.28, 0.28 ]
Eves 2006 -0.17 (0.45) 2.3 % -0.17 [ -1.05, 0.71 ]
Knebel 2000 -0.13 (0.26) 6.8 % -0.13 [ -0.64, 0.38 ]
Kurihara 1989 -0.58 (0.24) 8.0 % -0.58 [ -1.05, -0.11 ]
Laude 2006 -0.44 (0.16) 17.9 % -0.44 [ -0.75, -0.13 ]
McDonald 1995 -0.4 (0.29) 5.4 % -0.40 [ -0.97, 0.17 ]
O’Donnell 1997 -0.44 (0.16) 17.9 % -0.44 [ -0.75, -0.13 ]
Rooyackers 1997 (group 1) -0.26 (0.41) 2.7 % -0.26 [ -1.06, 0.54 ]
Rooyackers 1997 (group 2) -0.33 (0.42) 2.6 % -0.33 [ -1.15, 0.49 ]
Woodcock 1981 -0.72 (0.27) 6.3 % -0.72 [ -1.25, -0.19 ]
Total (95% CI) 100.0 % -0.42 [ -0.55, -0.28 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.89, df = 12 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 6.17 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.20. Comparison 1 Oxygen versus air, Outcome 20 Breathlessness - post-hoc - sensitivity analysis -
no imputed quantities and no outliers.
Review: Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease
Comparison: 1 Oxygen versus air
Outcome: 20 Breathlessness - post-hoc - sensitivity analysis - no imputed quantities and no outliers
Study or subgroup SMD (SE) SMD Weight SMD
IV,Random,95% CI IV,Random,95% CI
Eaton 2002 -0.42 (0.15) 25.3 % -0.42 [ -0.71, -0.13 ]
Lewis 2003 -0.1 (0.2) 19.9 % -0.10 [ -0.49, 0.29 ]
Nandi 2003 0.17 (0.24) 16.4 % 0.17 [ -0.30, 0.64 ]
O’Donnell 1997 -0.44 (0.16) 24.1 % -0.44 [ -0.75, -0.13 ]
Woodcock 1981 -0.72 (0.27) 14.3 % -0.72 [ -1.25, -0.19 ]
Total (95% CI) 100.0 % -0.31 [ -0.56, -0.05 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 8.58, df = 4 (P = 0.07); I2 =53%
Test for overall effect: Z = 2.39 (P = 0.017)
Test for subgroup differences: Not applicable
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Analysis 1.21. Comparison 1 Oxygen versus air, Outcome 21 Breathlessness - post-hoc - sensitivity analysis -
no end exercise and no outliers.
Review: Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease
Comparison: 1 Oxygen versus air
Outcome: 21 Breathlessness - post-hoc - sensitivity analysis - no end exercise and no outliers
Study or subgroup SMD (SE) SMD Weight SMD
IV,Random,95% CI IV,Random,95% CI
Davidson 1988 -0.22 (0.35) 3.7 % -0.22 [ -0.91, 0.47 ]
Eaton 2002 -0.42 (0.15) 20.0 % -0.42 [ -0.71, -0.13 ]
Killen 2000 -0.25 (0.34) 3.9 % -0.25 [ -0.92, 0.42 ]
Knebel 2000 -0.13 (0.26) 6.7 % -0.13 [ -0.64, 0.38 ]
Kurihara 1989 -0.58 (0.24) 7.8 % -0.58 [ -1.05, -0.11 ]
Lewis 2003 -0.1 (0.2) 11.3 % -0.10 [ -0.49, 0.29 ]
McDonald 1995 -0.4 (0.29) 5.4 % -0.40 [ -0.97, 0.17 ]
McKeon 1988a 0 (0.32) 4.4 % 0.0 [ -0.63, 0.63 ]
Nandi 2003 0.17 (0.24) 7.8 % 0.17 [ -0.30, 0.64 ]
O’Donnell 1997 -0.44 (0.16) 17.6 % -0.44 [ -0.75, -0.13 ]
Rooyackers 1997 (group 1) -0.26 (0.41) 2.7 % -0.26 [ -1.06, 0.54 ]
Rooyackers 1997 (group 2) -0.33 (0.42) 2.6 % -0.33 [ -1.15, 0.49 ]
Woodcock 1981 -0.72 (0.27) 6.2 % -0.72 [ -1.25, -0.19 ]
Total (95% CI) 100.0 % -0.31 [ -0.44, -0.18 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 11.50, df = 12 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 4.66 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.22. Comparison 1 Oxygen versus air, Outcome 22 Breathlessness - subgroup analysis - dyspnoea
measure.
Review: Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease
Comparison: 1 Oxygen versus air











IV,Random,95% CI IV,Random,95% CI
1 modified Borg
Dean 1992 -1.4 (0.56) 1.4 % -1.40 [ -2.50, -0.30 ]
Eaton 2002 -0.42 (0.15) 12.7 % -0.42 [ -0.71, -0.13 ]
Emtner 2003 (group 1) -0.33 (0.38) 2.8 % -0.33 [ -1.07, 0.41 ]
Emtner 2003 (group 2) -0.5 (0.4) 2.6 % -0.50 [ -1.28, 0.28 ]
Eves 2006 -0.17 (0.45) 2.1 % -0.17 [ -1.05, 0.71 ]
Jolly 2001 (group 1) -1.31 (0.64) 1.0 % -1.31 [ -2.56, -0.06 ]
Jolly 2001 (group 2) -1.22 (0.56) 1.4 % -1.22 [ -2.32, -0.12 ]
Kurihara 1989 -0.58 (0.24) 6.3 % -0.58 [ -1.05, -0.11 ]
Lewis 2003 -0.1 (0.2) 8.4 % -0.10 [ -0.49, 0.29 ]
McDonald 1995 -0.4 (0.29) 4.6 % -0.40 [ -0.97, 0.17 ]
O’Donnell 1997 -0.44 (0.16) 11.6 % -0.44 [ -0.75, -0.13 ]
Rooyackers 1997 (group 1) -0.26 (0.41) 2.5 % -0.26 [ -1.06, 0.54 ]
Rooyackers 1997 (group 2) -0.33 (0.42) 2.3 % -0.33 [ -1.15, 0.49 ]
Somfay 2001 -1.43 (0.64) 1.0 % -1.43 [ -2.68, -0.18 ]
Subtotal (95% CI) 60.7 % -0.44 [ -0.58, -0.29 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 13.11, df = 13 (P = 0.44); I2 =1%
Test for overall effect: Z = 5.78 (P < 0.00001)
2 VAS
Davidson 1988 -0.22 (0.35) 3.3 % -0.22 [ -0.91, 0.47 ]
Killen 2000 -0.25 (0.34) 3.5 % -0.25 [ -0.92, 0.42 ]
Knebel 2000 -0.13 (0.26) 5.5 % -0.13 [ -0.64, 0.38 ]
Laude 2006 -0.44 (0.16) 11.6 % -0.44 [ -0.75, -0.13 ]
McKeon 1988a 0 (0.32) 3.9 % 0.0 [ -0.63, 0.63 ]
Nandi 2003 0.17 (0.24) 6.3 % 0.17 [ -0.30, 0.64 ]
-1 -0.5 0 0.5 1
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IV,Random,95% CI IV,Random,95% CI
Woodcock 1981 -0.72 (0.27) 5.2 % -0.72 [ -1.25, -0.19 ]
Subtotal (95% CI) 39.3 % -0.25 [ -0.48, -0.02 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 8.29, df = 6 (P = 0.22); I2 =28%
Test for overall effect: Z = 2.15 (P = 0.032)
Total (95% CI) 100.0 % -0.37 [ -0.50, -0.24 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 23.31, df = 20 (P = 0.27); I2 =14%
Test for overall effect: Z = 5.60 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.81, df = 1 (P = 0.18), I2 =45%
-1 -0.5 0 0.5 1
Favours experimental Favours control
A D D I T I O N A L T A B L E S
Table 1. Overview of characteristics of included studies








O2 delivery O2 dose Jadad score




NA Mouthpiece 44% 3
Eaton 2006 Function 75 NA CRQ 17.1 NC 2 L/min 4




NA Mouthpiece 40% 4











Haidl 2004 Function 66.5 NA Modified
Borg








NA Mouthpiece 30% 5
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NA Mouthpiece 30% 5




0.4 (SD 0.5) NC 2 L/min 2





NA Mask 4 L/min 3
Eaton 2002 Sensation 69 (SD 7.5) NA Modified
Borg
0.7 (SD 1.0) NC 4 L/min 4
Jolly 2001
(group 1)
















NC 3 L/min 2
Maltais
2001
Function 85 (SD 4) NA Modified
Borg
NA Mouthpiece 75% 2









(range 0 to 3)
NC 5 L/min 3
Somfay
2001




NA Mouthpiece 30% 1





NA Mask 2 L/min 3
Knebel
2000
Both NA 97.1 (SD 1.
7) (range 92
to 100)
10 cm VAS 0.5 (SD 0.9)
(range 0 to 4.
7)
NC 4 L/min 5
Garrod
1999




NA NC 2 L/min 2
O’Donnell
1997












NA NC 4 L/min 1
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Function 71.3 (SD 15) NA Modified
Borg
NA NC 4 L/min 1
Ishimine
1995





NA Unknown 3 L/min 2
McDonald
1995
Function 69 (SD 8.5)
(range 58 to
82)
94 (SD 2.1) Modified
Borg
NA NC 4 L/min 4
Dean 1992 Function 71 (SE 2.6) NA Modified
Borg
NA Mouthpiece 40% 4
Leach 1992 Function 65.5 (SD 17.
6)
NA 10 cm VAS NA Mask 2 L/min 3
Kurihara
1989




NA NC 3 L/min 1
Davidson
1988
Function 64.51 (SE 2.
25)
NA 10 cm VAS NA NC or valve 4 L/min 2
McKeon
1988a








NA NC 2.5 L/min 2
McKeon
1988b
Function 66.4 (SD 11) NA 300 mm
VAS
NA NC 4 L/min 5
Swinburn
1984
Function NA 93.2 (SD 0.
8)
10 cm VAS NA Mouthpiece 60% 1
Woodcock
1981
Both 72 (SD 11.3) NA 10 cm VAS 4 (SD 0.94)
**














BL = baseline; NA = Not available; VAS = visual analogue scale; CRQ = chronic respiratory questionnaire; SD = standard deviation;
SE = standard error; LTOT = long term oxygen therapy; NC = nasal canula
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